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Background Despite our growing understanding of the pathophysiology and 
management of heart failure, there exist no strategies to individualize therapy using 
predictors of long-term prognosis and response to therapy.   Gene expression analysis 
using microarray technology provides a phenotypic resolution not possible with standard 
clinical criteria and could offer insights into disease mechanisms and also identify 
markers useful for diagnostic, prognostic, and therapeutic purposes.  Thus, the two major 
applications of this technology are gene discovery and molecular signature analysis.   
These two applications were explored in studies involving the two major forms of 
cardiomyopathy, ischemic and nonischemic (ICM and NICM, respectively).   
Methods  For a gene discovery analysis, we compared the gene expression of 21 NICM 
and 10 ICM samples with that of 6 nonfailing (NF) hearts using Affymetrix U133A 
microarrays and Significance Analysis of Microarrays software.   For molecular signature 
analysis, we identified and validated an etiology signature with Prediction Analysis of 
Microarrays software using 48 ICM and NICM myocardial samples obtained from 
different institutions and at different clinical stages.   
Results   The gene discovery analysis demonstrated that compared to NF hearts, 257 
genes were differentially expressed in NICM and 72 genes in ICM.  Only 41 genes were 
shared between the two comparisons and an analysis of the gene subsets revealed shared 
and unique disease-specific gene expression between end-stage cardiomyopathy of 
different etiologies.  The molecular signature analysis demonstrated that an etiology 
prediction profile accurately distinguished between ICM and NICM, was generalizable to 
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samples from separate institutions, specific to disease stage, and unaffected by 
differences in clinical characteristics.   
Conclusions   We have demonstrated that there are shared and distinct genes involved in 
the development of heart failure of different etiologies, and that a molecular signature can 
accurately identify etiology in cardiomyopathy.  These findings highlight the utility of the 
two distinct applications of gene expression analysis, and support ongoing efforts to 
develop cause-specific therapies and expression profiling-based biomarkers in heart 
failure.   The ultimate goal is individualized therapy, whereby a heart failure patient could, 
through gene expression analysis, be offered an accurate assessment of prognosis, and 
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The current state of heart failure management 
Heart failure therapy 
 The incidence of heart failure is rapidly increasing in the United States and is a 
major cause of morbidity and mortality.1  Over the past two decades, there have been 
remarkable advances in medical and surgical therapies designed to improve the 
symptoms and survival of patients with heart failure, including angiotensin-converting 
enzyme (ACE) inhibitors,2-4 beta-blockers,5-8 aldosterone antagonists,9;10 angiotensin-
receptor blockers,11-13 cardiac resynchronization therapy,14-16 implantable defibrillators,17-
19 and ventricular assist devices.20  
 However, it is still not clear which patients will benefit most from which therapies, 
and a better understanding of the differences in response to therapy is essential because 
there are an increasing number of interventions that may be costly, such as implantable 
cardiac defibrillators;21 risky, such as ventricular assist devices;20  or scarce, such as 
donor hearts for cardiac transplantation.22  
 In addition, the issue of polypharmarcy is looming.  Although the number of 
medications shown to improve mortality in heart failure is growing, the more medications 
an individual takes, the greater the risk of adverse effects.23  While large-scale clinical 
trials have shown overall improvements in quality of life and survival for heart failure 
patients, there are clearly subsets of patients who respond differently to therapies.  For 
example, ACE inhibitor intolerance is more common in patients with ischemic 
cardiomyopathy (ICM),24 milrinone has a deleterious effect in ICM but not nonischemic 
cardiomyopathy (NICM),25 amiodarone may prevent sudden death only in NICM, 26;27 
and the benefit of combination therapy with isosorbide dinitrate and hydralazine may be 
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greater in African-American heart failure patients.28  Thus, the ability to individualize 
therapy is critical, so that patients receive only those therapies from which they will 
derive benefit, while avoiding those which might lead to harm.    
Heart failure prognosis 
 Within the spectrum of heart failure, prognosis varies widely 29.  Although clinical 
indicators of poor prognosis exist, including increasing age;30 decreased ejection 
fraction;31 higher New York Heart Association functional class;32 diabetes mellitus;33  
worsening renal function;34 decreased sodium;35 increased B-type natriuretic peptide;36 
and increased uric acid;37 none have been shown to assist in tailoring the rapidly 
increasing array of pharmacologic, device, and surgical therapies for heart failure patients. 
Gaps in our understanding of heart failure  
 Which newly diagnosed cardiomyopathy patients will improve their ejection 
fraction and functional status, and which will go on to develop circulatory collapse and 
require cardiac transplantation, is still beyond our ability to assess.   Furthermore, we 
currently cannot determine which patients will benefit most from therapies with 
improvement in symptoms and survival, and which patients will have little benefit or 
even harm.   Gene expression analysis using microarray technology, by providing a 
phenotypic resolution not possible with standard clinical criteria, could provide better 
information regarding prognosis and response to therapy in heart failure patients. 
Microarray analysis 
Overview of microarray technology 
 With the emergence of microarray technology, it is now possible to 
simultaneously assess the expression of tens of thousands of gene transcripts, with 
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remarkable resolution of phenotypic characterization.   Microarrays rely on the principle 
of complementary hybridization of nucleotide sequences and have taken advantage of 
robotic technology to create platforms as small as a few inches wide containing 
thousands of DNA sequences (Figure 1.1A). 
 There are two types of microarrays.  The first type, traditionally known as a 
cDNA microarray, utilizes relatively long multimers of probe cDNA (500 – 5000 bases), 
is made primarily in individual institutions, and is often organ- or disease-specific.  
Examples include the CardioChip from Brigham and Women’s Hospital38 and the 
LymphoChip from Stanford University.39  Usually, two samples are studied on a single 
array, and relative gene expression is measured. 
 The second type of microarray, known as an oligonucleotide microarray, uses 
smaller DNA probes (20 – 80 bases) and has a number of advantages: 1) it is 
commercially produced by companies such as Affymetrix; Agilent, Amersham, or AME 
Bioscience, and thus the quality control is standardized and the cost of production is 
minimized;  2) it contains an unbiased genome-wide rather than organ system-specific set 
of probes;  3) it contains more gene transcripts (almost 50,000 on the newest Affymetrix 
2.0 GeneChip Array); 4) it measures absolute, as opposed to relative, gene expression 
because individual samples are studied on separate arrays. 
 Both cDNA and oligonucleotide microarrays consist of a solid support, usually a 
glass slide or a nylon membrane, onto which DNA sequences are attached.  Using high-
speed robotics, thousands of DNA sequences are either spotted using pins or an ink-jet 
printer or synthesized directly on the array using PCR or photolithography.  For a 
microarray experiment, RNA from a sample is extracted, transcribed into cDNA, labeled 
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with fluorescence (more common) or radioactivity, and then hybridized to the microarray.  
Complementary sequences remain bound to the array.  Expressed genes are identified by 
the position of the corresponding bound probes on the microarray and their abundance is 
determined by the intensity of the measured signal (Figure 1.1B).  Thus, an experiment 
with a single microarray can provide information on the expression thousands of genes 
simultaneously: the transcriptome of a given tissue sample can be determined. 
 The next essential step in microarray analysis is assurance of adequate array 
quality.  All arrays should be subject to quality control.  For example, if Affymetrix gene 
chips are used, there are parameters established by the manufacturer for assessing sample 
and array quality.40  These parameters include measurement of 260/280nm ratios of both 
total RNA and biotinylated cRNA to assess for RNA purity; visual inspection for the 
presence of image artifacts; and assessment of average background and noise value, 
exogenously added prokaryotic hybridization controls, percent present calls, scaling 
factors, and internal control genes, usually actin and glyceraldehyde phosphate 
dehydrogenase (GAPDH). Only arrays in which all parameters are within acceptable 
levels should be subject to further analysis. 
 The final step in microarray preparation is conversion of probe set data into gene 
expression levels.  Because each gene on a microarray is represented by multiple probes, 
the hybridization intensity of all these probes must be taken into account in determining 
the overall expression of each gene.  While many methods exist, the principles are the 
same and involve three steps: background and signal adjustment, data normalization, and 
summarization of probe information into gene expression levels.  Background and signal 
adjustment corrects for background noise, adjusts for cross hybridization, and ensures 
6 
that all values fall on the proper scale.  Normalization eliminates systematic differences 
between arrays, either using a reference array or the combined information from all the 
arrays.  Finally, summarization involves converting the multiple probe hybridization 
intensities on the array into a single measure of gene expression.   These background-
corrected, normalized, and converted probe summaries of gene expression can then be 
used for microarray analysis.    
Applications of microarray analysis 
 The challenge in microarray experiments is in the experimental design and 
statistical analysis, where the number of variables assessed is orders of magnitude higher 
than the number of individuals studied.  There is concern about the dangers of data-
mining, where lists of thousands of genes are generated without an understanding of the 
technical and statistical pitfalls of microarray analysis.  To avoid this, it is essential to 
understand the distinct applications of this technology. 
 Because the state of the transcriptome in a given diseased tissue may contain a 
highly accurate representation of key biological phenomena, patterns of gene expression 
have potential to provide insights into disease mechanisms and also to identify markers 
useful for diagnostic, prognostic, and therapeutic purposes.  Thus, the two distinct major 
applications of this powerful technology are gene discovery and molecular signature 
analysis, and these two applications have different goals, statistical methods, and 







 Gene discovery focuses on identifying differentially expressed genes 
characteristic of different disease states, through which novel genetic pathways and 
potential therapeutic targets may be elucidated.  In the field of cardiomyopathy, many 
microarray studies have focused on gene discovery.  Studies have offered insights into 
the differential gene expression of failing and nonfailing hearts,41-49  dilated and 
hypertrophic cardiomyopathy,50 and before and after left ventricular assist device 
(LVAD) support.51-55  
Statistical methods  
 Many statistical methods have been used to identify differentially expressed genes.  
All methods, however, rely on the same principles: comparing expression between two or 
more groups by taking into account the magnitude of the difference between groups and 
the variability of expression within groups while adjusting for multiple comparisons.   
The latter point is essential in microarray analyses, where the number of variables (i.e., 
thousands of genes) is orders of magnitude greater than the number of subjects. 
 Significance Analysis of Microarrays (SAM)56 is one approach to identify 
differentially expressed genes.  SAM uses a modified t-test statistic to determine the 
observed and expected relative differences in gene expression.  To calculate the observed 
relative difference in gene expression, d(i), the difference in average gene expression 
between the two groups is divided by the standard deviation of repeated measures of gene 
expression, s(i) and a constant, so to minimize the impact of genes with low levels of 
expression.  The expected relative difference is the average of the relative difference of 
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all possible permutations of the samples.  The observed relative difference in gene 
expression is then plotted against the expected relative difference, and this scatterplot is 
used to determine which genes are differentially expressed.  Differentially expressed 
genes are those displaced from the line of unity by a distance greater than the chosen 
threshold, and the threshold is chosen to minimize the false discovery rate. 
 Thus, SAM identifies genes with statistically significant changes in expression by 
identifying a set of gene-specific statistics (similar to the t-test, thus taking into account 
both magnitude of change and variability of expression) and a corresponding false 
discovery rate (similar to a p value adjusted for multiple comparisons).  Another common 
statistical method for identifying differentially expressed genes is the ANOVA test, used 
by commercially available software such as GeneSpring from Agilent. 
Validation  
 Once differentially expressed genes are identified, the transcript abundance is 
routinely confirmed by a complementary method, such as quantitative PCR, Northern 
blotting, or RNase protection assays.57  In cardiomyopathy, studies have relied mainly on 
quantitative PCR, with over 80% agreement in all studies with the results of microarray 
hybridization.41-50;52;53;55;58  Less commonly, levels of the corresponding protein have also 
been measured, with less agreement between transcript and protein abundance.53;54  
However, this is not surprising, since a number of factors affect the measured protein 
abundance, including differences in mRNA localization, processing, stability, translation 




Failing versus nonfailing hearts 
 Despite differences in sample size and statistical analyses, there is congruence 
between studies aimed at identifying differentially expressed genes between failing and 
nonfailing hearts.41-49   Significantly regulated genes across all studies are mainly those 
belonging to functional categories of cell growth and maintenance, 
cytoskeleton/sarcomere, metabolism, and signal transduction.  This agreement across 
studies offers further validation for studies of differential gene expression. 
 However, these studies have a number of limitations, including their focus on 
solely binary comparisons (failing versus nonfailing) and concentrating mainly on NICM.  
These limitations have limited their applicability and highlighted the need for more 
sophisticated analyses incorporating ICM samples along with samples of NICM and 
nonfailing hearts.   
Impact of left ventricular assist device support 
 A number of studies have also examined the changes in gene expression that 
occur following LVAD support.51-55   Through mechanical unloading of the failing 
ventricle, LVAD support results in beneficial hemodynamic, neurohormonal, structural, 
and biochemical changes, termed reverse remodeling.58  This phenotypic alteration, 
coupled with the availability of tissue samples obtained at the time of implantation, has 
offered a unique opportunity to study the transcriptomal shifts associated with reverse 
remodeling.  Many of these analyses have demonstrated alterations in genes involved in 
vascular signaling, including downregulation of neuropilin-1, a vascular endothelial 
growth factor receptor,55 upregulation of endothelial nitric oxide synthase,52 and 
upregulation of the APJ receptor for apelin, an endogenous cardiac inotrope present in the 
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cardiac vasculature.53  Thus, there is congruence in these studies as well, and different 
studies have all identified significant alterations in genes that regulate vascular 
organization and endothelial function in response to mechanical unloading of the failing 
human heart.  
 The most sophisticated of the analyses of LVAD-supported hearts compared the 
gene expression of nonfailing hearts with that of failing hearts with and without LVAD 
support to identify adaptations that represent normalization of gene expression.54   Of the 
3088 transcripts that were differentially expressed in failing relative to nonfailing hearts, 
only 238 actually demonstrated a consistent response to LVAD support and of these, 
more than 75% demonstrated persistence or exacerbation of their heart failure expression 
pattern after LVAD support.  This suggests that the alterations in gene expression 
following LVAD support are distinct from a return toward normalcy and may not 
represent a simple reversal of changes observed during disease progression.54  These 
findings offer unique insights into the nature of LVAD-associated reverse remodeling 
and could theoretically be clinically useful in identifying individual patient responses to 
mechanical unloading. 
Implications for molecular signature identification  
 Although the majority of microarray analyses in cardiomyopathy to date have 
focused on gene discovery, these studies nevertheless provide insight into the feasibility 
of molecular signature analysis.  In two studies, heart failure of different etiologies 
demonstrated different patterns of gene expression in unsupervised analyses.  An 
unsupervised analysis of gene expression does not take into account a priori definitions, 
such as clinical parameters of etiology or disease stage, in the division of samples into 
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groups.  Rather, a global assessment of gene expression alone is used to determine the 
relatedness of samples, and the significance of the grouping is then assessed.  In one 
study, the NICM  samples demonstrated more extensive global changes in gene 
expression than ICM samples following LVAD support.51  In another study, the overall 
gene expression of familial and alcoholic cardiomyopathy was distinct from that of 
idiopathic cardiomyopathy.48 
 Heart failure patients of different clinical stages also exhibit different patterns of 
gene expression in unsupervised analyses.  In one study of failing and nonfailing hearts, a 
distinct cluster of patients who were of the highest medical urgency status awaiting 
cardiac transplantation emerged in an unsupervised analysis.46     
 These findings suggest that gene expression can be correlated with clinically 
relevant parameters in heart failure patients.  However, because these studies focused on 
gene discovery, the observations could not be applied prospectively to identify and 
validate a gene expression signature to distinguish subjects based on these parameters, 
thus emphasizing the need for studies focused solely on molecular signature analysis. 
Molecular signature analysis  
Statistical methods  
 The goal of molecular signature analysis is to identify a pattern of gene 
expression that is associated with a clinical parameter, such as etiology, prognosis, or 
response to therapy, thus potentially providing greater diagnostic or prognostic precision 
than that currently available from standard clinical information.  There are a number of 
methods that can be used for molecular signature analysis, including partial least squares 
regression, neural networks, and shrunken centroids, and all rely on the same basic 
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principles.59-61  First, samples are divided into groups based on a clinically relevant 
parameter, such as disease etiology, prognosis, or response to therapy.  Then a molecular 
signature is created by choosing genes whose expression is solidly associated with the 
parameter in question, by weighting genes based on their individual predictive strengths. 
 Prediction Analysis of Microarrays (PAM) is one approach in molecular signature 
analysis.62  PAM uses the method of nearest shrunken centroids to identify and validate 
the smallest set of genes whose expression is associated with a predefined class. A 
standardized class centroid is the average expression of each gene in a given class divided 
by the within-class standard deviation.  The overall centroid is the average expression of 
each gene in all classes divided by the pooled within-class standard deviation.  
Standardization allows greater weight to be given to genes whose expression is stable 
within a class.  PAM creates shrunken centroids by shrinking the class centroids towards 
the overall centroid by a threshold amount.  Thus, the shrunken centroids are “de-noised” 
versions of centroids that act as prototypes for each class.  The threshold is chosen by 10-
fold cross validation.  In this process, gene expression prediction profiles with different 
numbers of genes (i.e., from different thresholds) are fit on the basis of 90% of the 
samples and then tested on the remaining 10%.  This process is executed multiple times, 
and the output is the error rate using different thresholds. The prediction profile is chosen 
as the smallest list of genes that can be used to predict the classification of an individual 
sample with the minimal error rate.62;63 
 To then classify independent samples, PAM computes each test sample’s squared 
distance from each of the class centroids. The predicted class is the one whose centroid is 
closest to the expression profile of the test sample.  In contrast to SAM and other 
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methods of identifying differentially expressed genes, PAM focuses mainly on the 
stability of gene expression and on the smallest number of genes required to create a 
molecular signature. 
Validation 
 While the goal of gene discovery is to identify differentially expressed genes 
which offer insight into novel genetic pathways or cause-specific therapies, the goal of 
molecular signature analysis is to identify a pattern of genes that differentiates between 
clinical entities with a precision not possible based on standard clinical information.  
Thus, the identity of the mRNA transcripts in the signature or whether they are translated 
into protein may or may not have immediately discernable bearing on the utility of the 
pattern.63  Therefore, the validation strategy is also unique: testing the accuracy of the 
identified molecular signature in samples distinct from those used to create it. 
Application of molecular signature analysis to neoplastic disease  
 In neoplastic disease, molecular signature analysis can determine prognosis and 
response to therapy.  In breast cancer, a molecular signature was identified that predicted 
disease outcome in young patients with breast cancer better than standard clinical and 
histological criteria: a poor prognosis signature was associated with a 5-fold increased 
risk of distant metastases in 5 years, a difference that would justify early intensive 
adjuvant chemotherapy.64  In large B-cell lymphoma, a molecular signature predicted 
survival better than standard clinical methods.65  Similar results have been obtained for 
acute myeloid leukemia66;67, chronic lymphocytic leukemia,68 prostate cancer69;70 and 
CNS tumors.71 
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 These advances in neoplastic disease have shown that molecular signature 
analysis can augment current standard practices to better individualize management and 
choose among treatment options.  It is essential to determine if the powerful predictive 
power of molecular signature analysis demonstrated in neoplastic disease can be applied 
to cardiovascular disease. 
Research plan 
 Clearly, gene expression analysis in cardiomyopathy is at its earliest stages.   The 
current dissertation utilizes the two major applications in gene expression analysis, gene 
discovery and molecular signature analysis.   First, while many studies have focused on 
gene discovery, most have involved small samples sizes and comparisons between two 
groups, such as failing and nonfailing hearts and before and after LVAD support.  We 
propose a more sophisticated analysis, of the changes in gene expression between ICM, 
NICM, and nonfailing hearts.  Identifying the shared and distinct genes involved in the 
development of heart failure of different etiologies may offer insight into cause-specific 
therapies for heart failure.  Second, to demonstrate that molecular signature analysis is 
feasible in cardiology, we have identified and validated a gene expression profile that 
differentiates between the two major forms of cardiomyopathy, ICM and NICM. 
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Table 1.1 Comparing gene discovery and molecular signature analysis 
 Gene Discovery Molecular Signature Analysis 
Goal of analysis Elucidate novel genetic 
pathways and therapeutic targets
Refine diagnosis and treatment  
What is identified Differentially expressed genes 
between disease states 
A pattern of genes that 
characterizes a clinical 
parameter: diagnosis, prognosis, 
or response to therapy 
Goal of validation Confirm levels of gene 
expression 
Assess the predictive accuracy 





RNase protection assays 
Apply the molecular signature 
to independent samples 
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 Figure 1.1 How microarray hybridization works.  A.  Schematic relating the microarray 
platform, probe sequences, and scanned, hybridized image.  The microarray is a solid 
support upon which nucleic acid probes corresponding to known gene transcripts are 
attached in specific locations.   B.  The many steps involved in microarray analysis.  
Total RNA is isolated from tissues samples and used to synthesize double-stranded 
cDNA which is then used as a template to make biotin-labeled cRNA.  Fragmented, 
biotin-labeled cRNA is hybridized to a microarray, containing nucleic acid probes 
attached to the solid support.  After washing, the microarray is scanned.  By monitoring 
the amount of label associated with each probe location, it is possible to infer the 
















Gene expression analysis of ischemic and nonischemic cardiomyopathy: 









*Adapted from Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, 
Conte JV, Tomaselli G, Garcia JGN, Hare JM. Gene expression analysis of ischemic and 
nonischemic cardiomyopathy: Shared and distinct genes in the development of heart 




 Dilated cardiomyopathy is a common cause of congestive heart failure, the 
leading cause of cardiovascular morbidity and mortality in the United States.1  Dilated 
cardiomyopathy can be initiated by a variety of factors, such as ischemia, pressure or 
volume overload, myocardial inflammation or infiltration, and inherited mutations.72  A 
prevailing hypothesis is that despite the varied inciting mechanisms that initiate the heart 
failure syndrome, there is a final common pathway that drives heart failure progression.73  
Because of this, there is limited research into specific molecular events that are unique to 
the underlying process.  This issue is especially relevant in the two major forms of 
cardiomyopathy, nonischemic (NICM) and ischemic (ICM), While NICM and ICM have 
similar presentations,74 they are characterized by different pathophysiology, prognosis, 
and response to therapy,24-27;29;33 and understanding their different pathophysiologic 
mechanisms is essential in guiding future therapies. 
 Microarray technology, with the ability to simultaneously assess mRNA levels of 
tens of thousands of genes, offers a novel approach to compare and contrast the 
myocardial transcriptome of NICM and ICM.  Although previous studies have examined 
changes in gene expression in failing versus nonfailing (NF) hearts,41;42;47-49 they have 
focused only on NICM.  The goal of this study was to simultaneously examine the 
differences in transcriptomes between NICM and ICM and NF hearts to establish a set of 
shared and unique genes differentially expressed in the two major causes of heart failure.  
The current analysis offers insight into both disease-specific pathogenesis and 
therapeutics.    Furthermore, an understanding of the distinctions with potential 
pathophysiologic underpinnings between these two conditions supports and complements 
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The study sample comprised 31 end-stage cardiomyopathy and 6 NF hearts.  
Myocardial tissue from end-stage cardiomyopathy patients was obtained at the time of 
left ventricular assist device (LVAD) placement or cardiac transplantation from two 
institutions: 1) Johns Hopkins Hospital in Baltimore, Maryland (n= 24 NICM and ICM 
samples and 6 NF samples) and 2) University of Minnesota in Minneapolis, Minnesota 
(n= 7 NICM samples).  Samples from the latter institution were collected and prepared 
independently,52 and gene expression data files were kindly provided. 
Discarded myocardial tissue from the left ventricular free wall or apex obtained 
during surgery was immediately frozen in liquid nitrogen and stored at -80° C.  The 
dissecting pathologist selectively excluded areas of visible fibrosis from the portion 
stored for analysis.  Because myocardial tissue obtained at LVAD placement and unused 
donor hearts are considered discarded tissue, we obtained an exemption from the Johns 
Hopkins Institution Review Board for sample collection and medical chart abstraction 
without written informed consent. 
Sample preparation 
ICM was defined as evidence of myocardial infarction on histology of the 
explanted heart.  In addition, all patients with ICM exhibited severe coronary artery 
disease (>75% stenosis of the left anterior descending artery and at least one other 
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epicardial coronary artery) and/or a documented history of a myocardial infarction.74;76  
NICM patients had no history of myocardial infarction, revascularization, or coronary 
artery disease and had all been diagnosed with idiopathic cardiomyopathy. 
Microarray hybridization 
 Myocardial RNA was isolated from frozen biopsy samples using the Trizol 
reagent and Qiagen RNeasy columns.   Double-stranded cDNA was synthesized from 5 
µg RNA using the SuperScript Choice system (Invitrogen Corp, Carlsbad, CA). Each 
double-stranded cDNA was subsequently used as a template to make biotin-labeled 
cRNA and 15 µg of fragmented, biotin-labeled cRNA from each sample was hybridized 
to an Affymetrix U133A microarray (Affymetrix, Santa Clara, California).  Affymetrix 
chip processing was performed at the Hopkins Program for Genomic Applications core 
facility.  The U133A microarray allows detection of 21,722 transcripts (15,713 full length 
transcripts, 4,534 non-expressed sequence tags (ESTs) and 1,475 ESTs). The quality of 
array hybridization was assessed by the 3’ to 5’ probe signal ratio of glyceraldehyde 
phosphate dehydrogenase (GAPDH) and actin.  Our samples had a ratio of 1-1.2, 
indicating acceptable RNA preparation. 
Data normalization 
We used the robust multi-array analysis (RMA) algorithm77;78 to pre-process the 
Affymetrix probe set data into gene expression levels for all 37 samples (the 30 samples 
prepared at our institution as described above and the 7 samples prepared at an outside 
institution52).  The gene expression data files are accessible through the NCBI Gene 
Expression Omnibus (GEO) database (accession numbers for series GSE1869; 
http://www.ncbi.nlm.nih.gov/geo/). 
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Differential gene expression  
 We identified differentially expressed genes in two comparisons: 1) NICM versus 
NF hearts and 2) ICM versus NF hearts.  Statistically significant changes in gene 
expression were identified using Significance Analysis of Microarrays (SAM).56  SAM 
identifies genes with statistically significant changes in expression by identifying a set of 
gene-specific statistics (similar to the t-test) and a corresponding false discovery rate 
(FDR; similar to a p-value adjusted for multiple comparisons).   We identified genes with 
a FDR of < 5% (corresponding to a p value adjusted for multiple comparisons < 0.05) 
and an absolute fold change of ≥ 2.0.  This threshold has been used in other similar 
studies47 and may maximize specificity.79   
 The differentially expressed genes were classified by the Gene Ontology 
Consortium system (www.geneontology.org) and were visualized by hierarchical 
clustering and heat mapping80 using Euclidean distance with complete linkage using 
software obtained at www.bioconductor.org. 
Validation 
 Levels of transcript normalized to GAPDH (a constitutively expressed gene) were 
compared between NICM and NF samples and between ICM and NF samples to confirm 
the up- or down-regulation of differentially regulated transcripts.  RNA was available 
from 4 NF, 5 ICM, and 10 NICM samples.  The RNA was treated with DNaseI to remove 
contaminating genomic DNA and subsequently used to synthesize cDNA.  Primers were 
designed using Primer Express 2.0 software.  Each sample was run on a GeneAmp 7900 
Sequence Detection System (PE Applied Biosystems) and analyzed using SDS software 
(Applied Biosystems).  For each gene of interest, a standard curve was generated using 
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serial dilutions of a control cDNA.  The quantity of gene transcript in unknown samples 
was estimated using this standard curve, with GAPDH as a normalizer.  SYBR green 




 Subjects with end-stage ICM (n= 10) or NICM (n= 21) exhibited severely 
reduced ejection fraction, left ventricular dilation, elevated pulmonary arterial and wedge 
pressures, and reduced cardiac index (Table 2.1).   Subjects with ICM were older, all 
male, more often on angiotensin-converting enzyme inhibitors, and less often on 
intravenous inotropic therapy.   Compared with no-LVAD patients, pre-LVAD patients 
had lower ejection fraction, higher pulmonary capillary wedge pressure, and lower 
cardiac index.  The NF hearts (n = 6) were from unused cardiac transplant donors.  The 
unused donor subjects were younger (median age 42 years with interquartile range 24-50 
years), predominantly male, and information on echocardiographic and hemodynamic 
parameters and medications was not available. 
Differential gene expression: NICM versus NF and ICM versus NF 
  There were 257 genes differentially expressed between NICM and NF samples 
and 72 genes differentially expressed between ICM and NF samples with a false 
discovery rate of < 5% and an absolute fold change of ≥ 2.0.  Of the differentially 




Differentially expressed genes common to both NICM-NF and ICM-NF comparisons 
 The majority of the 41 shared genes fell into functional classes of cell growth and 
maintenance and signal transduction (Figure 2.1).  The majority of the genes were up-
regulated in NICM and ICM hearts compared with NF hearts, and for all 41 shared genes, 
fold changes were remarkably similar in direction and magnitude between NICM-NF and 
ICM-NF comparisons (Table 2.2).  Notably, genes implicated in the fetal gene program 
were differentially expressed.  As the ventricle fails, there is a change in the ventricular 
gene expression pattern from the normal adult pattern to that normally observed only 
during fetal life, and these genes are known as the fetal gene program.81    
 Genes involved in the fetal gene induction included down-regulation of alpha 
myosin heavy chain polypeptide 682 and up-regulation of atrionatriuretic peptide receptor 
C in NICM and ICM relative to NF hearts.83  In the cell growth and maintenance class, 
there was up-regulation of hemoglobin alpha and beta chains.  There was also up-
regulation of genes involved in signal transduction, including endothelin receptor type A.  
In addition, there was significant regulation of genes encoding components of the 
cytoskeleton (up-regulation collagen type 21 alpha and down-regulation ficolin), and the 
extracellular matrix (up-regulation of asporin).      
Differentially expressed genes unique to the NICM-NF comparison 
 Of the 216 genes that were uniquely differentially expressed in  NICM samples, 
the majority fell into metabolism, cell growth and maintenance, signal transduction, and 
binding (Figure 2.1 and Table 2.3).  All genes were up-regulated in NICM hearts except 
one: a zinc transporter which was down-regulated 2-fold.  The genes involved in 
metabolism included angiotensin I-converting enzyme 2 (ACE2) and genes involved in 
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fatty acid and cholesterol metabolism (acyl-CoA synthetase long-chain family member 3 
and oxysterol binding protein-like 8).  In cell growth and maintenance, up-regulated 
genes included cyclin-dependent kinase inhibitor 1B and delta sleep inducing peptide, a 
vagal-potentiating peptide with influences on cardiac rhythm.84  Genes involved in 
signaling pathways were up-regulated, included signal transducer and activator of 
transcription 1 and 4, members of the JAK/STAT signaling pathway, as well as receptors 
for leptin, growth hormone, transforming growth factor beta, and platelet-derived growth 
factor.  Several genes implicated in inflammation and the immune response showed 
increased expression in NICM samples, including interleukin 27, an MHC molecule, and 
a component of the complement pathway, H factor 1. There were also several genes 
related to cell adhesion, apoptosis, and development.   
Differentially expressed genes unique to the ICM-NF comparison 
 The 31 genes uniquely differentially expressed between NF and ICM samples 
mainly belonged to functional classes of cell growth and maintenance, catalytic activity, 
and signal transduction (Figure 2.1 and Table 2.4).  They also included genes implicated 
in the fetal gene induction, including up-regulation of natriuretic peptide precursor B, 
atrial natriuretic factor, and an embryonic atrial myosin light chain polypeptide.72 
Differentially expressed genes and functional categories 
 To assess whether the difference in functional categories noted in the NICM-NF 
and ICM-NF comparisons was solely a function of their representation on the microarray 
platform, we compared the proportion of differentially expressed genes in the different 
functional categories with their proportional representation on the microarray platform. 
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 As shown in Figure 2.1, the majority of genes on the array (over 50%) belong to 
functional classes of binding and metabolism; a moderate number of genes (15-40%) are 
in the classes of catalytic activity, cell growth/maintenance, development, nucleus, signal 
transduction, and transcription; and few genes (less than 10%) belong to classes of 
apoptosis, cell adhesion, cytoskeleton, and inflammatory response (the combined 
percentages total over 100% since genes can belong to more than one functional 
category).  This pattern does not match that of our data (p < 0.001 in a χ2 test).  This 
suggests that the differences in functional categories identified between NICM-NF and 
ICM-NF comparisons were not solely a function of their representation on the microarray. 
Clustering 
 The heat maps with clustering algorithms for the two comparisons, ICM-NF and 
NICM-NF, are shown in Figure 2.2. The NF samples formed a distinct cluster from the 
ICM samples.  For the NICM-NF comparison, there were two dominant subclusters.  One 
subcluster contained only NICM samples obtained from patients at the time of LVAD 
implantation (NICM/pre-LVAD).  The other subcluster contained two subgroups: 1) 
predominantly NF samples and 2) the remaining portion of NICM samples, which were 
all obtained from patients who did not have an LVAD prior to cardiac transplantation 
(NICM/no-LVAD).  Thus, there was a clear discrimination among the NICM samples: 1) 
those from patients who required LVADs prior to cardiac transplantation and 2) those 
from patients who survived to cardiac transplantation without LVAD support. 
 To determine the specificity of the profiles, we also created a heat map with 
clustering algorithm for all 288 genes that were differentially expressed in at least one of 
the two comparisons (Figure 2.3).  Samples formed three distinct etiology clusters, but 
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this was likely due to the presence of shared differentially expressed genes.  To confirm 
the specificity of the differentially expressed genes, we created two additional heat maps 
with clustering (Figure 2.4): first, NF and ICM samples using only those genes identified 
as differentially expressed between NF and NICM samples, and second, NF and NICM 
samples using only those genes identified as differentially expressed between NF and 
ICM samples.  If, as we assumed, the genes uniquely identified as differentially 
expressed in ICM relative to NF hearts were truly unique to the ICM-NF comparison, 
then a heat map of these genes in NICM and NF hearts should demonstrate no clustering 
by etiology.  The same should be true for NICM genes in ICM hearts.  This was the case: 
as expected, in both heat maps, the samples did not cluster by etiology, indicating that the 
unique differentially expressed genes were specific to the given comparison. 
Validation 
 We selected 16 genes of potential biologic interest and validated the microarray 
findings in NICM, ICM, and NF hearts using QPCR.  As shown in Figure 2.5, QPCR 
confirmed 27 of the 32 microarray predictions with regard to fold change.  Of the 5 that 
did not agree on fold change, 3 were nonsignificantly changed in both comparisons (the 
leptin receptor in ICM, serine proteinase inhibitor, clade E, member 1 in NICM, and the 
acyl-CoA synthetase long-chain family member 3 in ICM), leaving only 2 clear 
disagreements: S100 calcium binding protein A8 was significantly down-regulated by 
QPCR but nonsignificantly up-regulated by microarray and lumican was significantly up-





 The principal finding of this investigation is that cardiomyopathies of different 
etiologies exhibit both shared and distinct changes in gene expression compared with NF 
hearts.  Remarkably, of more than 22,000 transcripts present on the Affymetrix 
microarray platform, only 288 genes (1-2%) are differentially expressed in NICM and 
ICM relative to NF hearts, and 41 of these genes are common to both comparisons with 
comparable fold changes.  This suggests that there are both shared and distinct 
mechanisms that contribute to the development of heart failure of different etiologies, and 
a better understanding of these distinctions supports ongoing efforts to develop cause-
specific therapies specifically targeted at NICM and ICM.85  
 The current study is unique for a number of reasons.  First, we have studied 37 
samples, which is large relative to gene expression studies in cardiomyopathy to 
date.41;42;47-53;55  There are no accepted means of calculating sample size and power in 
microarray experiments, but because our study examines a larger number of samples than 
prior studies, we have increased power to detect significant changes in gene expression.  
Furthermore, we have the added advantage of uniformity among samples: all NICM 
samples were from individuals with idiopathic cardiomyopathy, and their clinical 
characteristics were similar. 
 The second unique feature of this study is that we have compared not only NICM 
and NF hearts, as in many previous studies,41;42;48;49 but extended this analysis to compare 
the differential gene expression of NICM and ICM relative to NF hearts.  This offers 
further insight into the mechanisms involved in the development of heart failure of 
varying etiologies.  Many genes are shared between NICM and ICM relative to NF hearts, 
29 
and this is consistent with clinical experience: the presentations and standard treatment 
for cardiomyopathy of both etiologies is similar.1  However, despite similar presentations 
and therapies, NICM and ICM are distinct diseases; patients with ICM have decreased 
survival compared with their NICM counterparts,29;33 and respond differently to 
therapies.24-27  Thus, an understanding of the distinctions between the two conditions at 
the level of gene expression may guide future efforts to design etiology-based therapies. 
 The predominance of metabolism genes in NICM hearts suggests that the 
derangements involved in the genesis and maintenance of NICM may be metabolic in 
nature.  This is supported by an early trial of beta-blockers in heart failure which 
demonstrated a greater mortality benefit in NICM than ICM.5  Beta-blockers improve 
myocardial efficiency by shifting myocardial metabolism from free fatty acids to glucose.  
The increase in fatty acid metabolism genes specifically in NICM in our analysis would 
explain why beta-blockers may be particularly beneficial in NICM.  Furthermore, our 
results suggest that future etiology-specific therapies in NICM could target metabolic 
pathways, including those of fatty acid or cholesterol synthesis.  One particularly relevant 
example is ranolazine.  This investigational compound shifts myocardial cells from fatty 
acid to glucose metabolism and is currently being investigated as a treatment for 
myocardial ischemia.86  Based on our results, this drug may also be helpful in patients 
with NICM. 
 In ICM, on the other hand, our results suggest that abnormalities in catalytic 
activity may predominate.  Notably, our analysis demonstrated the down-regulation of a 
specific serine proteinase inhibitor which has an anti-ischemic protective effect in pigs 
subject to experimentally-induced myocardial ischemia.87  Thus, its down-regulation in 
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ICM samples may be a maladaptive response to ischemic injury.  Given our results, it 
may be possible that repletion of such an enzyme could be beneficial in patients with 
ICM. 
 Our work agrees to an extent with the findings of a similar analysis of differential 
gene expression by Steenman et al.,47 in which pooled samples of NICM and ICM were 
compared to one NF sample, and 95 differentially expressed genes were identified.  
When compared to our list of 288 genes, we found 8 genes in common (Table 2.5).  
There are a number of reasons why our results differed.  The prior study had only one NF 
heart, and it was from a patient with cystic fibrosis.  This heart is likely very different, not 
only in age, but also in hemodynamic parameters, from a heart from an unused cardiac 
transplant donor.  In addition, we used different statistical algorithms for normalization 
and identification of differentially expressed genes.  We normalized with RMA, which 
has been shown to offer better detection of differentially expressed genes than 
Affymetrix’s default preprocessing algorithm.78  We identified differentially expressed 
genes with Significance Analysis of Microarrays, which has been validated in a number 
of studies56;66;67;88 and may be more accurate than other commonly used methods for 
identifying differentially expressed genes, such as t-tests.89  In addition, our analysis may 
have more external validity because we studied more samples (37 versus 7 patients) with 
individually hybridized, as opposed to pooled, data.  Individual hybridization may be 
more accurate than pooling because it allows the estimation of the within-group variance 
for each gene.90 
 Some of the genes shown to be differentially expressed in our study have been 
previously identified as differentially expressed in studies of NF versus NICM hearts, 
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with remarkably similar fold changes between studies (Table 2.5).  Commonly identified 
genes include those involved in the fetal gene program,72 including natriuretic peptide 
precursor B, atrial natriuretic factor, cardiac muscle myosin heavy chain, and atrial alkali 
myosin light chain.  The majority of genes are up-regulated in NICM and ICM hearts 
versus NF hearts, and this has also been noted in prior studies.41;42;47-49  This is likely due 
to biologic differences, since prior studies all used different methods to normalize data 
and identify differentially expressed genes.  Furthermore, since the expression of many of 
these genes was confirmed with quantitative PCR in these prior studies, this offers 
indirect further confirmation of the validity of our differentially expressed genes.  This 
highlights the critical point in microarray analysis used for gene discovery: the results 
should be considered hypothesis-generating and the gene expression should be confirmed 
with other quantitative techniques, such as quantitative PCR.57 
 Through quantitative PCR, we confirmed the expression of 27 of the 32 
comparisons with 16 genes of interest in heart failure.  Of greatest interest are the novel 
genes from our analysis, including ACE2 and a member of the tumor necrosis factor 
receptor superfamily (TNFRSF11B, also known as osteoprotegerin).  We show that in 
subjects with end-stage cardiomyopathy, ACE2 is significantly up-regulated in NICM but 
not ICM.  ACE2 is expressed predominantly in vascular endothelial cells of the heart and 
kidney, and ACE and ACE2 have different biochemical activities. Angiotensin I is 
converted to angiotensin I–9 (with nine amino acids) by ACE2 but is converted to 
angiotensin II, which has eight amino acids, by ACE. Whereas angiotensin II is a potent 
blood-vessel constrictor, angiotensin I–9 has no known effect on blood vessels but can be 
converted by ACE to a shorter peptide, angiotensin I–7, which is a blood-vessel dilator.91  
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The up-regulation of ACE2 in NICM but not ICM cannot be ascribed to the increased 
prescription of ACE inhibitors in ICM subjects because unlike ACE, ACE2 is insensitive 
to inhibition by ACE inhibitors.92  Thus, our results offer insight into a possible new 
etiology-specific therapeutic target in heart failure. 
 Another novel finding of interest is the significant down-regulation of a member 
of the tumor necrosis factor receptor subfamily, TNFRSF11B in both NICM and ICM.  
Levels of tumor necrosis factor (TNF) are elevated in chronic heart failure93 and 
increasing levels of TNF have been correlated with disease severity.94  However, in 
clinical trials, soluble TNF-alpha antagonists did not reduce mortality or heart failure 
hospitalizations.95;96  One might speculate that this lack of benefit may relate to the down-
regulation of the TNF receptor in chronic heart failure. 
 The results of the unsupervised hierarchical clustering algorithm suggest that 
patients with NICM who do not undergo LVAD implantation resemble their NF 
counterparts more than patients with NICM patients who require an LVAD prior to 
cardiac transplantation.  An examination of their baseline characteristics confirms this: 
NICM-LVAD patients are a sicker subset, with higher pulmonary capillary wedge 
pressure and increased need for intravenous inotropes, two known markers of poor 
prognosis in chronic heart failure patients.97;98  While there are documented changes in 
gene expression between hearts before and after LVAD support,51-53;55 there is no 
evidence that differential gene expression exists between end-stage cardiomyopathy 
samples obtained before LVAD placement and at the time of cardiac transplantation or 
between patients with different clinical presentations.  Because this result was obtained 
with an unsupervised clustering algorithm, it is free of bias of predefined categories.63  
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While is it possible that the differences were due, in part, to the use of 7 NICM-LVAD 
samples from an outside institution, this is less likely because the outside institution 
samples themselves did not form a distinct cluster.  This unanticipated difference 
between end-stage NICM patients could offer insight into the differential gene expression 
of different stages of heart failure.  This requires further study, and lends credence to the 
notion that gene expression can be correlated with clinically relevant parameters in heart 
failure patients to aid in determining prognosis and response to therapy.  
 Although the analysis of gene expression using oligonucleotide microarrays is a 
powerful technique, limitations warrant mention.  Not all genes are represented on the 
Affymetrix U133A arrays used in this study, and therefore the knowledge that can be 
acquired from these experiments remains incomplete.  In addition, an unused donor heart 
is not the same as a normal heart, because circumstances causing to a donor heart being 
ineligible for cardiac transplantation, such as infection or prolonged hypotension, can 
also affect gene expression.  In fact, one study suggested that the differential gene 
expression identified between NICM and NF hearts may have been due to age and gender 
differences rather than differences in ventricular function.42  However, normal, age- and 
sex-matched hearts are impossible to obtain, and other researchers have used comparable 
unused donor hearts in their experiments.41;42;48;49 
 Another limitation of this study is that microarray analysis is essentially 
hypothesis generating.  However, in the tradition of such studies in the microarray 
literature,41-43;47-49;51-53 this is a hypothesis-generating analysis with biologic validation of 
select genes confirmed by QPCR.  We have followed the practice of other studies in the 
field, and extended the analysis to include more samples with different etiologies of heart 
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failure and a careful comparison with the results of prior studies (Table 2.5), which is 
unprecedented in the literature thus far.  For this reason, we believe that these analyses, 
while mainly hypothesis-generating, do have significant value and should be made 
available to other individuals interested in microarray analysis of ICM and NICM.   
 In conclusion, we offer a novel addition to the analysis of differential gene 
expression between failing and nonfailing hearts by providing new insight into the 
genetic pathways involved in the genesis of cardiomyopathy of different etiologies.  This 
analysis could provide a basis for future studies of cause-specific therapies in the 
complex management of heart failure patients.
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Table 2.1 Clinical characteristics of the study subjects used to identify differentially expressed genes between ischemic and 
nonischemic cardiomyopathy and nonfailing hearts 
 Ischemic  Nonischemic 
 No LVAD* 
(n = 7) 
Pre-LVAD† 
(n = 3) 
 No LVAD* 
(n = 8) 
Pre-LVAD* 
(n = 13) 
Age, y 54 (49 – 60) 60 (59 – 60)   51 (48 – 53) 46 (37 – 52) § 
Male 100% 100%  86% 62% 
Ejection fraction, % 20 (15 -25) 17.5 (10 – 25)  17. 5(7.5 – 27.5) 15 (12.5 – 20) 
LVIDd, cm  6.8 (6.7 – 7.6) 6.5 (6 – 7)  8.4 (7.5 – 9.3) 7.3 (6.8 – 8.1) 
PCWP, mm Hg 15 (12 – 23) 30 (30 – 32)  13.5 (13 – 14) 27 (21 – 31) ‡ 
Cardiac index, L·min1·m2 2.4 (2.3 -2 .4) 1.4 (1.3 – 1.5) ‡  2.4 (1.9 – 2.8) 1.5 (1.3 – 1.6) 
β-adrenergic antagonists 71% 67%  38% 36% 
ACE inhibitors or ARBs 100% 100%  88% 55% 
Diuretics 100% 100%  100% 64% 
Inotropic therapya 100% 33%  13% 73% ‡ 
Values are median (25th and 75th percentiles)*, median (range)†, or percentages.  ACE is angiotensin-converting enzyme, ARB is 
angiotensin receptor blocker, LVAD is left ventricular assist device; LVIDd is left ventricular end-diastolic diameter, PCWP is 
pulmonary capillary wedge pressure. 
‡ p < 0.05 for difference between no-LVAD and pre-LVAD groups. 
§ p < 0.05 for difference between ischemic and nonischemic cardiomyopathy. 
aIncludes dopamine, dobutamine, and milrinone.
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Table 2.2 Differentially expressed genes (n=41) shared between the ischemic-cardiomyopathy-versus-nonfailing heart and 
nonischemic-cardiomyopathy-versus-nonfailing-heart comparison  
Gene symbol Gene name ICM-NF NICM-NF 
  Fold change* FDR Fold 
change* 
FDR 
Cell growth/maintenance     
HBA2 hemoglobin, alpha 2 4.3 0.50 2.7 0.18 
HSAGL2  human alpha-globin gene  3.5 0.50 2.4 0.18 
HBB hemoglobin, beta 3.4 0.50 2.6 0.18 
HBA2 hemoglobin, alpha 2 3.4 0.50 2.2 0.18 
HBA1 hemoglobin, alpha 1 3.3 0.50 2.1 0.18 
AF059180  mutant beta-globin gene  3.0 0.50 2.4 0.18 
HBB hemoglobin, beta 3.0 0.50 2.6 0.18 
DUT dUTP pyrophosphatase 2.2 0.50 2.2 0.18 
RARRES1 retinoic acid receptor responder 1 -3.0 0.90 -2.2 0.52 
Signal transduction      
PIK3R1 phosphoinositide-3-kinase, reg subunit, polypeptide 1  3.1 0.50 2.3 0.18 
NPR3 atrionatriuretic peptide receptor C 3.1 0.50 2.5 0.18 
CBLB Cas-Br-M ectropic retroviral transforming sequence b 2.3 0.50 2.3 0.18 
EDNRA endothelin receptor type A 2.1 2.76 2.1 0.52 
DKFZp564I1922 Adlican 2.0 1.28 2.4 0.18 
TNFRSF11B tumor necrosis factor receptor superfamily, member 
11b  
-2.7 1.69 -2.0 1.18 
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SCYA2 small inducible cytokine A2  -3.5 0.90 -2.9 0.18 
Metabolism      
EIF1AY eukaryotic translation initiation factor 1A 2.2 0.50 2.2 0.60 
KIAA0669 KIAA0669 gene product 2.2 0.50 3.2 0.18 
SFPQ splicing factor proline/glutamine rich  2.1 0.50 2.0 0.18 
Nucleus      
PHLDA1 pleckstrin homology-like domain, family A, member 1 3.5 0.50 5.1 0.18 
PHLDA1 pleckstrin homology-like domain, family A, member 1 3.3 0.50 4.9 0.18 
ANP32E  acidic nuclear phosphoprotein 32 family, member E   2.0 0.50 2.7 0.18 
Cell adhesion/cell communication     
COL21A1 collagen, type XXI, alpha 1 2.3 0.50 2.3 0.18 
FCN3 ficolin 3 -3.2 0.90 -2.6 0.18 
Catalytic activity      
DBY DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 2.4 0.50 2.7 0.52 
AGXT2L1 alanine-glyoxylate aminotransferase 2-like 1 -2.5 0.90 -2.4 0.18 
Binding      
PEPP2 phosphoinositol 3-phosphate-binding protein-2 2.2 0.50 2.4 0.18 
QKI homolog of mouse quaking QKI  2.1 0.50 2.0 0.18 
Other      
MYT1 myelin transcription factor 1 2.0 0.90 2.4 0.18 
ASPN asporin (LRR class 1) 2.1 0.50 3.3 0.18 
MYH6 myosin, heavy polypeptide 6, cardiac muscle, alpha  -2.5 0.50 -3.7 0.18 
AF000381  folate binding protein mRNA, partial cds.  3.7 0.50 3.0 0.18 
TPR translocated promoter region  2.5 0.50 2.2 0.18 
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none Homo sapiens, clone IMAGE:4182947, mRNA 2.3 0.50 3.0 0.18 
none Homo sapiens, clone IMAGE:4182947, mRNA 2.3 0.50 3.1 0.18 
none Homo sapiens, clone IMAGE:3611719, mRNA 2.2 0.50 2.1 0.18 
none Homo sapiens cDNA FLJ11918 fis 2.2 0.50 2.8 0.18 
P311 similar to Neuronal protein 3.1  2.1 0.90 2.4 0.18 
none Human clone 23589 mRNA sequence 2.1 0.90 2.6 0.18 
HMG2 high-mobility group (nonhistone chromosomal) protein 
2 
2.1 0.50 3.1 0.18 
SERPINA3 serine (or cysteine) proteinase inhibitor,clade A, mem 3 -2.5 0.50 -2.0 0.18 
*Fold change described the mean gene expression for ischemic and nonischemic samples relative to nonfailing samples.  FDR is false 
discovery rate, analogous to a p value (as a percentage) adjusted for multiple comparisons. 
 
NICM-NF denotes comparison between nonfailing hearts and nonischemic cardiomyopathy samples 
ICM-NF denotes comparison between nonfailing hearts and ischemic cardiomyopathy samples 
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Table 2.3  Differentially expressed genes (n = 216) unique to the nonischemic-
cardiomyopathy-versus-nonfailing-heart comparison* 
Gene symbol Gene name Fold change* FDR 
Metabolism 
FACL3 acyl-CoA synthetase long-chain family member 3  2.8 0.18 
HNRPH3 heterogeneous nuclear ribonucleoprotein H3  2.7 0.18 
FLJ22222 hypothetical protein FLJ22222 (protein metabolism) 2.6 0.18 
OSBPL8 oxysterol binding protein-like 8 2.6 0.18 
ACE2 angiotensin I converting enzyme 2 2.6 0.68 
VDU1 pVHL-interacting deubiquitinating enzyme 1 2.4 0.18 
LIPA lipase A, lysosomal acid, cholesterol esterase  2.4 0.18 
MGEA5 meningioma expressed antigen 5  2.4 0.18 
FLJ12552 hypothetical protein FLJ12552 2.4 0.18 
CPE carboxypeptidase E 2.4 0.18 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 2.4 0.18 
SFRS7 splicing factor, arginine/serine-rich 7  2.3 0.18 
YT521    splicing factor YT521-B, KIAA1966 2.3 0.18 
SMARCA2 SWI/SNF related, matrix assoc, actin dep reg of chromatin 2.3 0.18 
GLS Glutaminase 2.3 0.18 
CTSB cathepsin B 2.3 0.18 
RNASE4 ribonuclease, RNase A family, 4 2.3 0.18 
DPYD dihydropyrimidine dehydrogenase 2.3 0.18 
GATM glycine amidinotransferase  2.3 0.18 
HSP105B heat shock 105kD 2.2 0.18 
GATM glycine amidinotransferase  2.2 0.18 
PIGK phosphatidylinositol glycan, class K 2.2 0.18 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 2.2 0.18 
BACE beta-site APP-cleaving enzyme 2.2 0.18 
NBS1 Nijmegen breakage syndrome 1  2.1 0.18 
LUC7A cisplatin resistance-associated overexpressed protein 2.1 0.18 
UBE1C ubiquitin-activating enzyme E1C  2.1 0.18 
GCH1 GTP cyclohydrolase 1  2.0 1.2 
C15orf15 chromosome 15 open reading frame 15 2.0 0.18 
FBXO3 F-box only protein 3 2.0 0.18 
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ODC1 ornithine decarboxylase 1 2.0 0.18 
B3GALT3 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 3 
2.0 0.52 
SEPP1 selenoprotein P, plasma, 1 2.0 0.18 
SLC39A8    solute carrier family 39, member 8  -2.0 0.18 
Cell growth/maintenance 
NAP1L3 nucleosome assembly protein 1-like 3 3.1 0.18 
ARID4B   AT rich interactive domain 4B  2.5 0.18 
CDKN1B cyclin-dependent kinase inhibitor 1B  2.5 0.18 
RNPC2 RNA-binding region containing 2 2.4 0.18 
DUSP6 dual specificity phosphatase 6 2.3 0.18 
NAP1L1 nucleosome assembly protein 1-like 1 2.3 0.18 
DENR density-regulated protein 2.3 0.18 
CENTB2 centaurin, beta 2 2.2 0.18 
TOB1 transducer of ERBB2, 1 2.2 0.18 
SEC23A Sec23 homolog A  2.2 0.18 
SNAP23 synaptosomal-associated protein, 23kD 2.2 0.18 
ID4 inhibitor of DNA binding 4, dominant negative helix-loop-
helix protein 
2.2 0.18 
SEC24B SEC24 related gene family, member B  2.2 0.18 
CGI-142 hepatoma-derived growth factor 2 2.2 0.18 
BMI1 B lymphoma Mo-MLV insertion region  2.2 0.18 
ABCA8 ATP-binding cassette, sub-family A, member 8 2.1 0.18 
BC003689  high-mobility group nucleosomal binding domain 2  2.1 0.18 
GAPCENA rab6 GTPase activating protein  2.1 0.18 
PURA purine-rich element binding protein A 2.1 0.18 
NUP153 nucleoporin 153kD 2.1 0.18 
PLSCR4 phospholipid scramblase 4 2.1 0.18 
NAB1 NGFI-A binding protein 1  2.1 0.18 
TRIM33 tripartite motif-containing 33 2.1 0.18 
DSIPI delta sleep inducing peptide, immunoreactor 2.1 0.18 
CTBP2 C-terminal binding protein 2 2.1 0.18 
JJAZ1 joined to JAZF1 2.1 0.18 
ZFHX1B zinc finger homeobox 1b 2.0 0.18 
ZNF161 zinc finger protein 161 2.0 0.18 
SERP1 stress-associated endoplasmic reticulum protein 1 2.0 0.18 
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Signal transduction 
APM1 adipocyte, C1Q and collagen domain containing    3.5 0.52 
SH3BGRL SH3 domain binding glutamic acid-rich protein like 3.1 0.18 
ARHI ras homolog gene family, member I 2.7 0.18 
ERBB2IP erbb2 interacting protein 2.6 0.18 
P23 unactive progesterone receptor, 23 kD 2.5 0.68 
SH3BP5 SH3-domain binding protein 5  2.4 0.18 
GHR growth hormone receptor 2.4 0.18 
APP amyloid beta precursor protein  2.4 0.18 
STAT1 signal transducer and activator of transcription 1, 91kD 2.4 0.18 
TCF7L2 transcription factor 7-like 2  2.4 0.18 
PDE4B phosphodiesterase 4B, cAMP-specific  2.3 0.52 
STC1 stanniocalcin 1 2.3 0.52 
TGFBR3 transforming growth factor, beta receptor III  2.3 0.18 
LEPR leptin receptor 2.3 0.18 
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 2.2 0.18 
PENK proenkephalin 2.1 0.18 
ATP6IP2 ATPase, H+ transporting, lysosomal interacting protein 2 2.1 0.18 
IGFBP3 insulin-like growth factor binding protein 3 2.1 0.18 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 2.1 0.18 
OGN osteoglycin  2.1 0.18 
LIM LIM protein  2.1 0.18 
AKAP11 A kinase anchor protein 11 2.1 0.18 
TCF7L2 transcription factor 7-like 2  2.1 0.18 
PDGFC platelet derived growth factor C 2.1 0.18 
NCOA2 nuclear receptor coactivator 2 2.0 0.18 
Binding 
KIAA0882 KIAA0882 protein 2.3 0.18 
TRIM22 tripartite motif-containing 22 2.3 0.18 
KIAA0993 WD repeat and FYVE domain containing 3  2.2 0.18 
BC017580 stress 70 protein chaperone, microsome-associated, 60kDa    2.2 0.18 
SE70-2 cutaneous T-cell lymphoma tumor antigen se70-2 2.2 0.18 
EPS15 epidermal growth factor receptor pathway substrate 15 2.2 0.18 
MYCBP2 MYC binding protein 2 , KIAA0916 2.2 0.18 
MATR3 matrin 3 2.2 0.18 
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PLAGL1 pleiomorphic adenoma gene-like 1 2.1 0.18 
KIAA0853 KIAA0853 protein 2.1 0.18 
ZZZ3 zinc finger, ZZ domain containing 3 , DKFZP564I052 2.1 0.18 
MATR3 matrin 3 2.1 0.18 
CRI1 CREBBP/EP300 inhibitory protein 1 2.1 0.18 
FMR1 fragile X mental retardation 1 3.3 0.18 
Transcription factors 
YY1 YY1 transcription factor 2.4 0.18 
SP3 Sp3 transcription factor 2.4 0.18 
RBBP1 retinoblastoma binding protein 1 2.3 1.2 
NR2F2 nuclear receptor subfamily 2, group F, member 2 2.3 0.18 
SOX4 SRY (sex determining region Y)-box 4 2.3 0.18 
STAT4 signal transducer and activator of transcription 4 2.1 0.18 
ELK3 ELK3, ETS-domain protein  2.1 0.18 
Inflammation/immune response 
HF1 H factor 1 (complement) 2.5 0.18 
NR3C1 nuclear receptor subfamily 3, group C, member 1 2.1 0.18 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 2.3 0.18 
IL27 interleukin 27 2.0 0.52 
Development 
LUM lumican 2.8 0.18 
FRZB frizzled-related protein 2.1 0.18 
DIXDC1    DIX domain containing 1, KIAA1735 2.0 0.18 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 2.0 0.18 
OSF-2 periostin, osteoblast specific factor    3.0 0.18 
Cell adhesion 
PNN pinin, desmosome associated protein 2.3 0.68 
LAMB1 laminin, beta 1 2.3 0.18 
DPT dermatopontin 2.2 0.18 
Catalytic activity 
HNMT histamine N-methyltransferase 2.2 0.18 
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 2.1 0.18 
PHKB phosphorylase kinase, beta 2.1 0.18 
DKFZP586A052
2 
DKFZP586A0522 protein 2.0 0.18 
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Apoptosis 
BNIP3L BCL2/adenovirus E1B 19kD interacting protein 3-like 2.2 0.18 
SPF30 survival motor neuron domain containing 1   2.2 0.18 
TIA1 TIA1 cytotoxic granule-associated RNA binding protein 2.1 0.18 
BCL2 B-cell CLL/lymphoma 2 2.0 0.18 
Cytoskeleton 
DMD dystrophin  2.2 0.18 
ADD3 adducin 3  2.1 0.18 
KLHL2 kelch-like 2, Mayven  2.0 0.18 
Other 
KTN1 kinectin 1 (kinesin receptor) 2.7 0.18 
C8orf2 chromosome 8 open reading frame 2 2.2 0.18 
GCC2    GRIP and coiled-coil domain containing 2 , KIAA0336 2.0 0.18 
AF054589  I-mfa domain-containing protein    2.2 0.18 
EFA6R ADP-ribosylation factor guanine nucleotide factor 6 3.0 0.18 
AF130089  Homo sapiens clone FLB9440 PRO2550 mRNA, complete 
cds.  
2.9 0.18 
AF130082  Homo sapiens clone FLC1492 PRO3121 mRNA, complete 
cds.  
2.9 0.18 
AF070641 Homo sapiens clone 24421 mRNA sequence 2.7 0.18 
AF271775  Homo sapiens DC49 mRNA, complete cds.  2.7 0.18 
CG005 phosphonoformate immuno-associated protein 5  2.6 0.18 
KIDINS220 likely homolog of rat kinase D-interacting substance of 220 
kDa 
2.6 0.18 
ALEX3 ALEX3 protein 2.5 0.18 
KIAA0680 chromosome 6 open reading frame 56  2.5 0.18 
FLJ11273 hypothetical protein FLJ11273 2.4 0.18 
UBQLN2 ubiquilin 2 2.4 0.18 
DICER1    Dicer1, Dcr-1 homolog (Drosophila) 2.4 0.18 
RYBP RING1 and YY1 binding protein 2.4 0.18 
TEB4 similar to S. cerevisiae SSM4 2.3 0.18 
IPW imprinted in Prader-Willi syndrome 2.3 0.52 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 2.3 0.18 
SP329 likely ortholog of mouse modulator of KLF7 activity    2.3 0.18 
SDCCAG1 serologically defined colon cancer antigen 1 2.3 0.52 
MARCKS myristoylated alanine-rich protein kinase C substrate 2.3 0.18 
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AK027252 Homo sapiens clone 23664 and 23905 mRNA sequence 2.3 0.18 
EPS8 epidermal growth factor receptor pathway substrate 8 2.3 0.18 
AK055910 Homo sapiens cDNA FLJ31348 fis, clone MESAN2000026 2.2 0.18 
KIAA0143 KIAA0143 protein 2.2 0.18 
AK025583 Homo sapiens cDNA clone  2.2 0.18 
KIAA0914 family with sequence similarity 13, member A1    2.2 0.18 
STAG2 stromal antigen 2 2.2 0.18 
AL136139  Contains 3' part of the gene for enhancer of filamentation 
(HEF1) 
2.2 0.18 




PTN pleiotrophin  2.2 0.18 
MGC4276 HESB like domain containing 2  2.2 0.18 
LOC51110 lactamase, beta 2  2.2 0.18 
GATA6 GATA binding protein 6 2.2 0.18 
AK021980 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 2.2 0.18 
AK025216 Homo sapiens cDNA: FLJ21563 fis, clone COL06445 2.2 0.18 
none chromosome 6 open reading frame 111: DKFZp564B0769 2.2 0.18 
AK021980 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 2.2 0.18 
13CDNA73 hypothetical protein CG003 2.1 0.18 
GASP    G protein-coupled receptor-associated sorting protein , 
KIAA0443  
2.1 0.18 
PSIP2 PC4 and SFRS1 interacting protein 2 2.1 0.18 
ARL5 ADP-ribosylation factor-like 5 2.1 0.18 
KIAA0582 KIAA0582 protein 2.1 0.18 
FLJ23018 hypothetical protein FLJ23018 2.1 0.18 
none hypothetical protein DKFZp761K1423 2.1 0.52 
STAG2 stromal antigen 2 2.1 0.18 
SACS spastic ataxia of Charlevoix-Saguenay (sacsin) 2.1 0.18 
AW190289 ESTs 2.1 0.18 
KIAA1109 KIAA1109 protein 2.1 0.18 
KPNB3 karyopherin (importin) beta 3 2.1 0.18 
TTC3 tetratricopeptide repeat domain 3 2.1 0.18 
AK055600 Homo sapiens mRNA; cDNA DKFZp434G012  2.1 0.18 
HHL    expressed in hematopoietic cells, heart, liver , KIAA0471 2.1 0.18 
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RCP Rab coupling protein 2.1 0.18 
FLJ22104 hypothetical protein FLJ22104 2.1 0.18 
BTN3A3 butyrophilin, subfamily 3, member A3 2.1 0.18 
BCMP1 transmembrane 4 superfamily member 10    2.1 0.18 
AV712064  EST:  Homo sapiens cDNA: DCAAUD05, 5'end, human 
dendrites  
2.1 0.18 
RNF38    ring finger protein 38 , FLJ21343 2.1 0.18 
AL049998 Homo sapiens mRNA; cDNA DKFZp564L222  2.1 0.18 
HS696H22  Human DNA sequence from clone RP4-696H22  2.1 0.18 
BC007568 Homo sapiens, clone IMAGE:3028427, mRNA, partial cds 2.1 0.18 
DICER1 Dicer1, Dcr-1 homolog (Drosophila) 2.1 0.18 
HS21C048  Homo sapiens chromosome 21 segment HS21C048.  2.1 0.18 
XPO1 exportin 1 (CRM1 homolog, yeast) 2.0 0.18 
ALEX1 ALEX1 protein 2.0 0.18 
KIAA0372 KIAA0372 gene product 2.0 0.18 
DC8 DKFZP566O1646 protein 2.0 0.60 
FAM3C family with sequence similarity 3, member C, GS3786 2.0 0.18 
AL713745 Homo sapiens mRNA; cDNA DKFZp761J0523  2.0 0.18 
TTC3 tetratricopeptide repeat domain 3 2.0 0.18 
TTC3 tetratricopeptide repeat domain 3 2.0 0.18 
UNC84A    unc-84 homolog A (C. elegans), KIAA0810 2.0 0.18 
OAZIN ornithine decarboxylase antizyme inhibitor 2.0 0.18 
ZNF292  ZNF292   zinc finger protein 292 , KIAA0530 2.0 0.18 
PJA2  praja 2, RING-H2 motif containing , KIAA0438 2.0 0.18 
HNRPA3 heterogeneous nuclear ribonucleoprotein A3 2.0 0.18 
HS73M23  ESTs  2.0 0.18 
RECQL RecQ protein-like (DNA helicase Q1-like) 2.0 0.18 
DR1 down-regulator of transcription 1, TBP-binding (negative 
cofactor 2) 
2.2 0.18 
AL049437 Homo sapiens mRNA; cDNA DKFZp586E1120  2.2 0.18 
*Fold change described the mean gene expression for ischemic and nonischemic samples 
relative to nonfailing samples.  FDR is false discovery rate, analogous to a p value (as a 
percentage) adjusted for multiple comparisons.
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Table 2.4  Differentially expressed genes (n = 31) unique to the ischemic-
cardiomyopathy-versus-nonfailing heart comparison* 




RPS4Y ribosomal protein S4, Y-linked 2.4 0.50 
ALS2CR3 amyotrophic lateral sclerosis 2 chromosome region, 
candidate 3 
2.3 0.50 
KPNB2 karyopherin beta 2 2.1 0.50 
SLC16A7 solute carrier family 16, member 7 2.1 0.50 
ZNF145 zinc finger protein 145  2.1 1.1 
Catalytic activity 
SERPINB1† serine (or cysteine) proteinase inhibitor, clade B, 
member 1 
-2.2 0.90 
SERPINB1† serine (or cysteine) proteinase inhibitor, clade B, 
member 1 
-2.2 2.4 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide -2.3 0.90 




NPPB natriuretic peptide precursor B 4.4 2.8 
HSCDDANF Human cardiodilatin-atrial natriuretic factor  2.3 3.8 
PBEF pre-B-cell colony-enhancing factor -2.1 3.7 
Transcription factors 
ATF3 activating transcription factor 3 -2.6 3.0 
SMAP31 homeodomain-only protein -3.3 0.90 
Inflammation/immune response 
PTX3 pentaxin-related gene, rapidly induced by IL-1 beta -2.2 3.0 
S100A8 S100 calcium binding protein A8 (calgranulin A) -2.7 0.90 
Development 
ARIH2 ariadne homolog 2  2.0 0.50 
DLK1 delta-like 1 homolog  2.0 2.9 
Metabolism 
PLA2G2A phospholipase A2, group IIA  -3.4 0.90 
Cytoskeleton 
MYL4 myosin, light polypeptide 4, alkali; atrial, embryonic 2.4 2.0 
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Other 
AF116676 EMBL:  Homo sapiens PRO1957 mRNA, complete 
cds. 
2.3 2.4 
TXNIP thioredoxin interacting protein 2.3 0.50 
SYNPO2L synaptopodin 2-like 2.1 0.50 
FLJ11539 hypothetical protein FLJ11539 2.1 0.50 
FLJ10159 hypothetical protein FLJ10159 2.0 0.50 
none Homo sapiens cDNA FLJ11918 fis, clone 
HEMBB1000272 
2.0 0.50 
DKFZP434F0318 hypothetical protein DKFZp434F0318 2.0 2.0 
none Homo sapiens cDNA: FLJ22179 fis, clone HRC00920 2.0 0.50 
CD163 CD163 antigen -2.0 0.90 
none Homo sapiens cDNA FLJ30298 fis, clone 
BRACE2003172 
-2.0 0.90 
none Homo sapiens cDNA: FLJ21545 fis, clone COL06195 -3.0 0.90 
*Fold change described the mean gene expression for ischemic and nonischemic samples 
relative to nonfailing samples.  FDR is false discovery rate, analogous to a p value (as a 
percentage) adjusted for multiple comparisons. 
†There are two entries for this gene product because it was identified as differentially 
expressed with two unique Affymetrix accession numbers.
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 Table 2.5 Differentially expressed genes between ischemic and nonischemic 
cardiomyopathy and nonfailing hearts common to previously published reports 
 Fold change 
 




Tan 48 Barrans 41 Yung 49 Steenman 47 
PHLDA1  5.1  3.5   5.43  
PIK3R1  2.3  3.1    2.73 
TPR  2.2  2.5   2.02  
COL21A1  2.3  2.3   3.52  
EIF1AY  2.2  2.2  1.78   
MYH6 -3.7 -2.5   -5.3 -1.36 
FCN3 -2.6 -3.2   -7.7  
NPPB   4.4  3.3   7.24 
MYL4   2.4  2.01  3.79 
HSCDDANF   2.3  4.2 19.15  4.83 
ZNF145   2.1    2.33 
ATP1B3  -2.3   -2.7  
PLA2G2A  -3.4 -5.1    
FMR1 3.3    2.06  
SH3BGRL 3.1     1.20 
OSF-2 3.0  12 1.96   
LUM 2.8  3.8    
HNRPH3 2.7    1.83  
HF1 2.5   1.23   
CDKN1B 2.5    2.03  
PDE4B 2.3   2.41   
PTN 2.2    3.29  
ATP6IP2 2.1   1.19   
GAPCENA 2.1    1.74  
TIA1 2.1   2.14   
PLAGL1 2.1    2.2  
NR3C1 2.1    1.72  
DSIPI 2.1     1.29 
FBXO3 2.0    1.59  
ODC1 2.0    2.52  
Gene symbols correspond to gene products as noted in Tables 2.2-2.4. 
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Figure 2.1  Percent of known genes in each functional category that were significantly 
regulated in both  nonischemic (NICM) and ischemic (ICM) cardiomyopathy compared 
to nonfailing (NF) hearts (black bars), unique to NICM hearts (light gray bars), unique to 
ICM hearts (white bars), and the representation of these functional categories on the array 
(dark grey bars).  There is no correlation with the representation of genes on the array and 
distribution of genes in the comparisons.  APO is apoptosis, BIN is binding, CAT is 
catalytic activity, CEL is cell adhesion, CGM is cell growth/maintenance, CYT is 
cytoskeleton, DEV is development, INF is inflammatory response, MET is metabolism, 





Figure 2.2  Hierarchical clustering of genes significantly regulated in ischemic (ICM; A) 
and nonischemic cardiomyopathy (NICM; B) compared to nonfailing (NF) hearts 
considered separately.  Each row represents a gene and each column represents a sample.  
Sample prefixes “T” denotes end samples from patients at the time of cardiac 
transplantation without left ventricular assist devices (no-LVAD); “LC” denotes samples 
obtained from patients at the time of LVAD placement (pre-LVAD), and “N” denotes 
nonfailing samples.  The suffix “i” denotes ICM samples.  The suffix “ni” denotes NICM 
samples.  The color in each cell reflects the level of expression of the corresponding gene 
in the corresponding sample, relative to its mean level of expression in the entire set of 
samples.  Expression levels greater than the mean are shaded in blue, and those below the 
mean are shaded in red.  Circled samples denote the predominant etiology clusters and 
samples labeled with an arrow fall outside of their appropriate cluster. A.  NF versus ICM. 
The no- and pre-LVAD samples do not form distinct clusters. B.  NF versus NICM.  The 




 Figure 2.3  Hierarchical clustering of genes significantly regulated in nonischemic 
cardiomyopathy (NICM) and ischemic cardiomyopathy (ICM) compared to nonfailing 
(NF) hearts considered together.  All 288 genes that were differentially expressed in 
either the NICM-NF or ICM-NF comparison are included.  Each row represents a gene 
and each column represents a sample.  Sample prefixes “T” denotes end samples from 
patients at the time of cardiac transplantation without left ventricular assist devices 
(LVADs); “LC” denotes samples obtained from patients at the time of LVAD placement 
(pre-LVAD), and “N” denotes nonfailing samples.  The suffix “i” denotes ICM samples.  
The suffix “ni” denotes NICM samples.  The color in each cell reflects the level of 
expression of the corresponding gene in the corresponding sample, relative to its mean 
level of expression in the entire set of samples.  Expression levels greater than the mean 
are shaded in blue, and those below the mean are shaded in red.  Circled samples denote 
the predominant etiology clusters.
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Figure 2.4  Hierarchical clustering of genes significantly regulated in  nonischemic 
cardiomyopathy tested in ischemic cardiomyopathy and nonfailing hearts (A) and 
regulated in ischemic cardiomyopathy tested in nonischemic cardiomyopathy and 
nonfailing hearts (B).  Each row represents a gene and each column represents a sample.  
Sample prefixes “T” denotes end samples from patients at the time of cardiac 
transplantation without left ventricular assist devices (LVADs); “LC” denotes samples 
obtained from patients at the time of LVAD placement (pre-LVAD), and “N” denotes 
nonfailing samples.  The suffix “i” denotes ischemic cardiomyopathy samples.  The 
suffix “ni” denotes nonischemic cardiomyopathy samples.  A.  Nonfailing versus 
ischemic cardiomyopathy using those genes identified as differentially expressed in the 
nonfailing-nonischemic comparison.  The samples do not form distinct etiology clusters.  
B.  Nonfailing versus nonischemic cardiomyopathy using only those genes identified as 
differentially expressed in the nonfailing-ischemic comparison.  The samples do not form 







Figure 2.5  Independent assessment of gene expression levels by quantitative PCR for 
select genes differentially expressed in ischemic and nonischemic cardiomyopathy 
relative to nonfailing  hearts.  Fold change in expression in nonischemic (NICM) and 
ischemic (ICM) hearts compared with nonfailing (NF) hearts according to QPCR (black 
bars) and microarrays (gray bars).  ACE2,  angiotensin-converting enzyme 2;  ATP1B3, 
ATPase, Na+/K+ transporting, beta 3 polypeptide; FACL3, acyl-CoA synthetase long-
chain family member 3; HBA2, hemoglobin A2; LEPR, leptin receptor; LUM, lumican; 
MYH6, myosin heavy chain 6; NAP1L3, nucleosome assembly protein 1-like 3; NPR3, 
atrionatriuretic peptide receptor C; PHLDA1, pleckstrin homology-like domain family A 
member 1; RPS4Y, ribosomal protein S4, Y-linked; S100A8, S100 calcium binding 
protein A8; SERPINE1, serine (or cysteine) proteinase inhibitor,clade E, member 1; 
SLC39A8, solute carrier family 39, member 8;  TNFRSF11B, tumor necrosis factor 
receptor superfamily member 11b; TXNIP,  thioredoxin interaction protein.  * P < 0.05 
compared with NF hearts by Wilcoxon rank sum test.  † P < 0.05 by Significance 
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 Molecular signature analysis through gene expression profiling has the potential 
to refine diagnostic and prognostic accuracy in a variety of diseases.  This technique has 
enjoyed widespread success in solid and hematological malignancies62;64-67;99;100 and may 
soon be employed in clinical trials.  While the ability to refine diagnosis and predict 
patient outcome has tremendous importance in myocardial diseases, the application of 
molecular signature analysis is in its earliest stages.  Small studies offer novel insights 
into gene expression in failing and nonfailing hearts,41-43;47-49 dilated and hypertrophic 
cardiomyopathy,50 and before and after ventricular assist device placement.51-53;55  
However, gene expression analysis has not yet been used to distinguish clinically relevant 
cardiovascular disease subtypes.  In fact, molecular signature analysis for 
cardiomyopathy is considered controversial due to the contention that, unlike tumors, 
there is a final common pathway independent of etiology for the progression of 
myocardial disease.73  
 The aim of this study was to test the hypothesis that molecular signature analysis 
using gene expression profiling could discriminate between the two major forms of 
cardiomyopathy, ischemic (ICM) and nonischemic (NICM).  We demonstrate that this 
methodology is applicable to samples obtained in different institutions and is specific to 
disease stage.   This study establishes proof-of-principle that gene expression signatures 
have the potential to refine the evaluation and treatment of heart failure patients, where 
management decisions may vary based on disease etiology.21;24;25;29;33;101  Our findings 
strongly support ongoing efforts to incorporate gene expression-based biomarkers in 
determining prognosis and response to therapy in heart failure. 
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Materials and methods 
Patients 
The study comprised 48 samples.  Myocardial tissue from different disease stages 
was obtained: 1) at left ventricular assist device (LVAD) placement or cardiac 
transplantation (n = 25 “end-stage”); 2) following LVAD support (n = 16; “post-
LVAD”); and 3) from prospectively collected newly diagnosed patients at 
endomyocardial biopsy (n = 7; “biopsy”).  Samples were from two institutions: 1) the 
Johns Hopkins Hospital (n = 34) and 2) the University of Minnesota (n = 14).  Samples 
from the latter institution were collected and prepared independently,52  and the gene 
expression data files were kindly provided. 
Written informed consent was obtained from all patients undergoing 
endomyocardial biopsy for sample collection and medical chart abstraction. Myocardial 
tissue obtained at LVAD placement, following LVAD support, or at cardiac 
transplantation, however, is considered discarded tissue.  Therefore, we obtained an 
exemption from the Johns Hopkins Institution Review Board for its collection and 
medical chart abstraction without written informed consent.  
 ICM was defined as histological evidence of ischemic injury and all ICM patients 
exhibited severe coronary artery disease (>75% stenosis of the left anterior descending 
artery and at least one other proximal epicardial artery) and/or a documented history of 
myocardial infarction.76  NICM patients had no history of myocardial infarction, 
revascularization, or coronary artery disease.  Newly diagnosed patients were those 
presenting or referred to the Johns Hopkins Hospital with a new diagnosis of 
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cardiomyopathy and symptoms for 6 months or less29 for further diagnostic evaluation, 
which included endomyocardial biopsy. 
Sample collection 
For end-stage and post-LVAD samples, discarded myocardial tissue from the left 
ventricular free wall or apex obtained during surgery was immediately frozen in liquid 
nitrogen and stored at -80° C.  The dissecting pathologist selectively excluded areas of 
visible fibrosis from the portion stored for analysis. 
For biopsy samples, patients referred to the Johns Hopkins Hospital with a newly 
diagnosed cardiomyopathy underwent endomyocardial biopsy as part of their evaluation.  
Right heart catheterization was performed from the right internal jugular vein.  
Endomyocardial biopsy of the distal RV septum was performed with a Mansfield 2.2 mm 
jaw size bioptome (Boston Scientific Corp., Watertown, MA) under fluoroscopic 
guidance to ensure proper positioning of the biopsy forceps. A portion of the biopsy, two 
samples of endomyocardium weighing 2-4 g, were immediately frozen in liquid nitrogen 
and stored at -80° C. 
Microarray hybridization 
 Myocardial RNA was isolated from frozen end-stage and post-LVAD samples 
using the Trizol reagent and Qiagen RNeasy columns.   For biopsy samples, RNA 
isolation included additional steps with a microhomogenizer (Fisher Scientific 
International, Pittsburgh, PA) and an RNAqueous-micro isolation kit (Ambion Inc, 
Austin, TX), and 50 ng total RNA as a starting material were subjected to two-round 
amplification using the  BioArray RNA Amplification and Labeling kit (Enzo Life Sci., 
Inc., Farmingdale, NY).   For end-stage samples, double-stranded cDNA was synthesized 
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from 5 µg RNA using the SuperScript Choice system (Invitrogen Corp, Carlsbad, CA).  
Each double-stranded cDNA was subsequently used as a template to make biotin-labeled 
cRNA and 15 µg of fragmented, biotin-labeled cRNA from each sample was hybridized 
to an individual Affymetrix U133A microarray (Affymetrix, Santa Clara, California).  
Affymetrix chip processing was performed at the Hopkins Program for Genomic 
Applications core facility.  The U133A is an oligonucleotide microarray that allows 
detection of 21,722 transcripts (15,713 full length, 4,534 non-expressed sequence tags 
(ESTs), and 1,475 ESTs). 
Quality control 
 All the arrays were subject to quality control according to the parameters 
established by Affymetrix for assessing sample and array quality.40  These parameters 
included measurement of 260/280nm ratios of both total RNA and biotinylated cRNA; 
visual inspection for the presence of image artifacts; and assessment of average 
background and noise value, exogenously added prokaryotic hybridization controls, 
percent present calls, scaling factors, and internal control genes (actin and glyceraldehyde 
phosphate dehydrogenase (GAPDH)). Only arrays in which all parameters were within 
acceptable levels were subject to further analysis.  Specifically, our samples had a ratio of 
< 3.0, indicating acceptable RNA preparation and ICM and NICM samples had similar 
proportions of present calls (45 – 48%). 
Data normalization 
We used the robust multiarray average (RMA) algorithm77;78 to normalize the 
Affymetrix probe set data into gene expression levels for all 48 samples.  Both the 
samples from the Johns Hopkins Hospital and those collected and prepared at the 
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University of Minnesota52 were normalized in the same manner.   There are four stages to 
RMA.  First, probe-set data from all arrays are simultaneously normalized using quantile 
normalization, which eliminates systematic differences between GeneChips without 
significantly altering the relative intensity of probes within a GeneChip.  Second, the 
mean optical background level for each array is estimated, and the intensity for each 
probe is adjusted to remove this.  Third, the normalized, background-corrected data is 
transformed to the log2 scale.  Finally, a median-polish procedure is used to combine 
multiple probes into a single measure of expression for each gene on each array.  
Although we initially normalized the data with Affymetrix’s default preprocessing 
algorithm (MAS 5.0), we found that RMA resulted in classifiers with better predictive 
power. These results are consistent with a publication showing that RMA provides better 
detection of differentially expressed genes than MAS 5.0.78  
Filtering 
 In order to create the gene expression signature using only genes that were 
differentially expressed in ICM versus NICM samples, we first analyzed the microarrays 
with Significance Analysis of Microarrays (SAM).56  SAM identifies genes with 
statistically significant changes in expression by identifying a set of gene-specific 
statistics (similar to the t-test) and a corresponding false discovery rate (FDR; similar to a 
p value adjusted for multiple comparisons).   At a FDR of 10%, there were 3332 
differentially expressed genes between ICM and NICM.  These 3332 genes were then 





To develop a gene expression signature that distinguished ICM from NICM, we 
employed Prediction Analysis of Microarrays (PAM)62 implemented in the R package for 
statistical computing, and a number of prediction analyses were performed (Figure 3.1).  
Sixteen end-stage cardiomyopathy samples (6 ICM and 10 NICM) from Johns Hopkins 
Hospital formed a training set to develop the etiology signature.  There were three test 
sets to validate the signature: 1) the remaining 9 end-stage cardiomyopathy samples, 
including 7 from the University of Minnesota; 2) 16 post-LVAD samples; and 3) 7 
biopsy samples. 
 Because the accuracy of the signature could differ based on the random division 
of samples into training and test tests, the above analysis was repeated with 210 random 
partitions of the samples into a 16-sample training set and 9-sample test set to determine 
the overall accuracy.  Each random partition identified different, overlapping sets of 
genes, but a 90-gene signature repeatedly minimized the cross-validation error.  We 
applied PAM to the entire set of 25 end-stage samples to identify the 90-gene signature as 
the representative etiology molecular signature. 
 The genes in the etiology molecular signature were classified by the Gene 
Ontology Consortium system (www.geneontology.org) and the signature was visualized 
by hierarchical clustering and a heat map (www.bioconductor.org) using Euclidean 
distance with complete linkage. 
Statistical analysis 
 Continuous variables were summarized by the median and quartiles and groups 
were compared using the Wilcoxon rank sum test. Categorical variables were 
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summarized by proportions and compared using Fisher's exact test. Sensitivity was 
defined as the proportion of ICM samples correctly classified by the gene expression 
signature, and specificity was defined as the proportion of NICM samples correctly 
classified. 
  To assess if the accuracy of the etiology molecular signature was affected by 
baseline clinical characteristics (including age, gender, systolic function, and medication 
use) as well as differences in etiology, we divided the 25 end-stage cardiomyopathy 
subjects into multiple two-way strata based on age (≥ or < 50 years), systolic function (≥ 
or < 15%), and use of intravenous inotropes.  We then assessed the representative 
etiology signature’s sensitivity and specificity over these strata by determining the 
proportion of subjects within each stratum that were correctly classified as having ICM or 
NICM. 
Quantitative PCR 
 Levels of transcript normalized to GAPDH (a constitutively expressed gene) were 
compared between ICM and NICM end-stage samples to confirm the up- or down-
regulation of select genes in the etiology signature.  RNA samples were treated with 
DNaseI to remove contaminating genomic DNA and subsequently used to synthesize 
cDNA.  Primers were designed using Primer Express 2.0 software.  Each sample was run 
on a GeneAmp 7900 Sequence Detection System (PE Applied Biosystems) and analyzed 
using SDS software (Applied Biosystems).  For each gene of interest, a standard curve 
was generated using serial dilutions of a control cDNA.  The quantity of gene transcript 
in unknown samples was estimated using this standard curve, with GAPDH as a 
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 All end-stage patients exhibited severely reduced ejection fraction, left ventricular 
dilation, elevated pulmonary arterial and wedge pressures, and reduced cardiac index 
(Table 3.1).   Compared with end-stage NICM patients, end-stage and post-LVAD ICM 
patients were older and all male.  In addition, compared with end-stage NICM patients, 
end-stage ICM patients were all on angiotensin-converting enzyme (ACE) inhibitors and 
less often on intravenous inotropes.  Hemodynamic and remodeling indices were similar 
between end-stage ICM and NICM patients.  Newly diagnosed ICM patients were older 
than their NICM counterparts with better remodeling indices.   
 Diagnostic accuracy 
 We developed an etiology signature using a training set of samples that, when 
applied to independent end-stage ICM and NICM samples, demonstrated 100% 
sensitivity and 100% specificity.  This perfect accuracy was also achieved in a test set 
where the majority of samples were from an institution distinct from that used to create 
the signature. 
 We assessed whether the etiology signature was affected by disease stage.  In 
post-LVAD samples, the gene expression signature correctly classified all NICM samples 
(n=13; specificity 100%), but only classified 1 of 3 ICM samples correctly (sensitivity 
33%).  In biopsy samples from patients with newly diagnosed cardiomyopathy, the 
signature again correctly classified all NICM samples (n = 4; specificity 100%), but only 
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classified 1 of 3 ICM samples correctly (sensitivity 33%).   The overall accuracy over 
210 random partitions of training and test sets was sensitivity 89% (95% CI 75 – 100%) 
and specificity 89% (95% CI 60 – 100%).   
Effect of clinical characteristics 
 We examined the signature’s predictive accuracy in strata based on each clinical 
characteristic (Table 3.2).  All the ICM patients were male and on ACE inhibitors so we 
could not ascertain if the signature would apply to women with ICM who were not on 
ACE inhibitors.  However, within each stratum, the sensitivity and specificity were 
similar and all were comparable to the overall sensitivity and specificity. 
Characterization of the etiology prediction signature  
Over 210 combinations of training and test set samples, the greatest accuracy was 
achieved with signatures containing 90 genes.  A 90-gene expression signature exhibited 
perfect accuracy 30% of the time.  The majority of genes in the representative etiology 
prediction profile were involved in signal transduction, metabolism, and cell 
growth/maintenance (Figure 3.2).  Most were up-regulated in ICM with an average fold 
change of 1.9 ± 0.9 (Table 3.3). 
 In a hierarchical clustering algorithm, 11 of the 16 ICM samples and 30 of the 32 
NICM samples formed a distinct cluster (Figure 3.3).  Whereas the biopsy samples 
clustered together, the samples did not cluster by pre- or post-LVAD status or by 
institution of origin. 
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Quantitative PCR 
 Levels of transcript for four genes in the etiology signature were confirmed using 
quantitative PCR (Figure 3.4).  In all four cases, the direction of the fold change by 
microarray and quantitative PCR were the same. 
 
Discussion  
 The major new finding of this report is the identification of a gene expression 
signature that accurately distinguishes ICM and NICM.  The signature was applicable to 
samples from different laboratories and, for NICM, was independent of disease stage.  
Gene expression signatures have been successfully correlated with etiology and outcome 
in oncology.62;64-67;99;100  There is an equal need to refine diagnostic and prognostic 
techniques in myocardial diseases, but advances have been restricted by limited tissue 
access.  Our findings demonstrate that gene expression signatures can accurately identify 
etiology in cardiovascular disease, and support ongoing efforts to incorporate gene 
expression-based biomarkers in determining prognosis and response to therapy. 
While the main focus of this study was proof-of-principle, a gene expression 
signature that distinguishes ICM and NICM could provide a valuable adjunct to 
diagnostic imaging and metabolic tools.  ICM and NICM are distinct diseases; patients 
with ICM have decreased survival compared to their NICM counterparts29;33;33 and 
respond differently to therapies.21;24;25;101  An etiology molecular signature would offer 
diagnostic insight, especially in patients with heart failure out of proportion to their 
coronary artery disease, up to 11% in one observational study.76  
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 Although we have demonstrated that end-stage cardiomyopathy can be accurately 
classified by gene expression, a more relevant signature would focus on newly diagnosed 
patients.  Therefore, we also tested the end-stage etiology signature in 7 endomyocardial 
biopsy samples collected from patients with newly diagnosed cardiomyopathy.  The 
signature performed perfectly in NICM while only one of three ICM samples was 
classified correctly.  This suggests that, compared with NICM patients, those with ICM 
exhibit greater changes in gene expression as disease progresses.  These results parallel 
those from post-LVAD patients and emphasize the need for stage-specific molecular 
signatures.  To our knowledge, this is the first evidence that microarray hybridization 
from endomyocardial biopsies is feasible; this success encourages future studies of gene 
expression signatures using endomyocardial biopsies with RNA amplification. 
Prior studies have shown that cardiomyopathy of different etiologies exhibits 
different patterns of gene expression.48;51  However, these studies did not develop or 
prospectively validate a gene expression signature.  In fact, one study comparing the gene 
expression of ICM and NICM found no differentially expressed genes.47  This study used 
pooled samples from only two ICM and two NICM patients, and likely did not have 
adequate resolution to detect changes in gene expression.102 
 Although the differential gene expression between failing and nonfailing hearts 
has been attributed to age and gender differences,42 this analysis has not been extended to 
ICM and NICM.  However, we addressed this possibility by stratifying our analysis by 
clinical characteristics.  The sensitivity and specificity were not affected, indicating that 
the etiology molecular signature’s accuracy is not an artifact of differences in baseline 
characteristics. 
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 Many of the genes in the etiology signature are not known to be expressed in 
myocardial tissue.  This discrepancy has been observed in prior microarray experiments 
in cardiomyopathy42;43;47-53;55 and stems from the gap between the number of genes on the 
microarray platform and our ability to define their functions.85  However, the inability to 
justify the biologic validity of every gene in the signature does not invalidate its clinical 
utility.  In prediction analysis, it is the pattern of gene expression, rather than the 
individual genes themselves, which serves as biomarkers of disease.57;62;63  
 Nevertheless, there is biologic plausibility for a number of genes in the etiology 
molecular signature.  The up-regulation of signal transduction genes in ICM, including 
several protein phosphatases and a MAP kinase, is supported by evidence that their gene 
products may protect against ischemic injury.103-105  The up-regulation of endothelin-
converting enzyme in ICM over NICM has also been described.106  One would expect up-
regulation of genes involved in cell growth/maintenance, including ribosomal and cell 
division cycle proteins, since myocyte proliferation rate is higher in ICM than NICM.107   
However, while these findings support the biologic validity of the etiology signature, the 
changes bear further investigation with a study focused on differential gene expression.44 
 Gene expression analysis is considered hypothesis-generating until validated by 
another technique.  Unlike the majority of studies in cardiology, where microarray 
analysis focuses on the discovery of novel genetic pathways, our analysis concentrates on 
prediction.  Thus, validation involves evaluating the predictive accuracy of the signature 
in independent, blinded samples.57;59;63  This is an established approach among studies in 
the cancer literature.64;66;67  However, the level of transcript abundance should also be 
confirmed with quantitative PCR to determine if the signature offers utility independent 
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of the microarray platform.  We confirmed the expression level of four genes in the 
prediction profile using quantitative PCR, and the fold changes agreed in all cases. 
 Several methodologic aspects of this study warrant mention.  There is little 
information regarding sample size requirements in microarray analysis.  One study 
determined that for accurate class prediction of etiology, a training set of 10-20 samples 
is required.102  Thus our sample size was adequate for prediction.  We were also able to 
maximize the amount of information obtained by random partitioning of samples.  
Furthermore, to our knowledge, this study includes the largest number of samples in a 
cardiovascular microarray study to date. 
 Finally, it may be argued that a gene expression signature that identifies patients 
based on prognosis would be more clinically valuable than one based on etiology, which 
can be determined by other methods.  The current findings are valuable proof-of-concept 
that other predictions will be possible in the future.  Indeed, the transition from gene 
profiling of etiology62;99;100 to gene profiling of prognosis,64-67 represents the path taken in 
the oncology experience. 
 This study represents the first use of gene expression signatures in cardiovascular 
disease and the first evidence that microarray hybridization from endomyocardial 
biopsies is feasible.  Microarray analysis has the potential to optimize the diagnosis and 
management of patients with myocardial diseases.  These results form the basis for future 
studies using molecular signatures to distinguish cardiomyopathy patients by other 
relevant clinical parameters.  Studies are currently underway to develop gene expression 
signatures that distinguish ICM and NICM in newly diagnosed patients, as well as to 
differentiate these patients by prognosis and response to therapy. 
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Table 3.1 Clinical characteristics of the study subjects used to identify and validate a molecular signature that differentiates between 
ischemic and nonischemic cardiomyopathy 




(n = 15) 
Ischemic† 
(n = 3) 
Nonischemic* 
(n = 13) 
Ischemic† 
(n = 3) 
Nonischemic† 
(n = 4) 
Age, y 57.5 (54-60) 46 (37-52) ‡ 60 (43-61) 46 (35-51) 63 (57-81) 45 (37-64) 
Male 100% 67%§ 100% 62% 66% 75% 
NYHA classification 4 (3-4) 4 (3-4) 3 (3-4) 3 (3-4) 2.5(2-2.5) 2.8 (2 - 3)║ 
Left ventricular ejection fraction, % 18.8 (15.0-25.0) 15.0 (10.0-20.0) N/A N/A 20 (12.5-32.5) 20 (15 -27.5) 
Left ventricular end-diastolic diameter, cm  6.8 (6.4-7.3) 7.4 (6.8-8.3) N/A N/A 4.7 (4.6-5.6) 6.3 (4.9-6.6)║ 
Pulmonary artery pressure, mm Hg       
     Systolic 49 (35-64) 50 (45-57) N/A N/A 47 (46-71) 64 (37-81) 
     Diastolic 25 (18-33) 30 (24-30) N/A N/A 22 (20-36) 30 (19-35) 
Pulmonary capillary wedge pressure, mm Hg 27 (14-31) 25 (20-30) N/A N/A 17 (15-27) 26 (11-33) 
Cardiac index, L·min1·m2 2.2 (1.5-2.4) 1.5 (1.3 – 1.9) N/A N/A 2.0  (1.4 – 2.3) 1.9 (1.8 – 2.2) 
Medications       
     Beta antagonists 70% 39% 33% 42% 66% 25% 
     ACE inhibitors  100% 62%‡ 66% 50% 100% 100% 
     Diuretics 100% 69% 33% 25% 100% 75% 
     Intravenous inotropic therapy# 10% 62%‡ 0% 0% 0% 0% 
*Values are median (25th and 75th percentiles) or percentages.      
†Values are median (range) or percentages. 
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‡p < 0.05 for end-stage ischemic vs nonischemic cardiomyopathy  
§p = 0.06 for end-stage ischemic vs nonischemic cardiomyopathy 
║p < 0.05 for end-stage vs biopsy subjects and post-LVAD vs biopsy subjects 
#Dopamine, dobutamine, or milrinone. 
N/A is not available, since routinely, post-LVAD patients do not undergo right heart catherization and ejection fraction lacks clinical 
relevance in patients receiving mechanical circulatory support.
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Table 3.2  Sensitivity and specificity of the etiology molecular signature in strata defined 
by clinical covariates 
 Sensitivity Specificity 
Overall 89% 89% 
Age, y   
   ≥ 50 88% 80% 
   < 50 100% 90% 
Ejection fraction, %   
   ≥ 15 89% 89% 
   < 15 100% 83% 
Inotropic therapy   
   Yes 100% 100% 
   No 89% 60% 
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Table 3.3  Genes (n = 90) in the molecular signature that differentiates between ischemic 
and nonischemic cardiomyopathy 
Gene accession 
no. 
Gene symbol Gene name Fold 
change* 
Cell growth/maintenance 
AL078621 RPL23AP7 ribosomal protein L23a  2.4 
AA086229 ENIGMA enigma (LIM domain protein) 2.2 
NM_005938 MLLT7 myeloid/lymphoid leukemia  2 
AA054734 CIZ1 CDKN1A interacting zinc finger protein-1 1.6 
AA576621 CDC2L5 cell division cycle 2-like-5  1.5 
NM_000076 CDKN1C cyclin-dependent kinase inhibitor-1C  1.5 
NM_003547 HIST1H4G histone-1 1.5 
BC005174 ATF5 activating transcription factor-5 1.4 
NM_015487 GEMIN4 gem-associated protein-4 1.4 
BC000229 MIS12 homolog of yeast Mis12 -1.5 
Cytoskeleton 
U40572 SNTB2 syntrophin, beta-2  1.9 
NM_007284 PTK9L protein tyrosine kinase-9-like  1.8 
AI077476 DMN desmuslin 1.5 
NM_014016 SACM1L SAC1 suppressor of actin mutations-1-like  -1.9 
Development 
NM_001420 ELAVL3 Hu antigen C 2.5 
AF005081 NA Homo sapiens skin-specific protein 2 
Immune response 
NM_030882 APOL2 apolipoprotein L-2 2.4 
NM_030754 SAA2 serum amyloid-A2 2.4 
L34163 IGHM immunoglobulin heavy constant mu 2.3 
AA742237 BAT2 HLA-B associated transcript-2 2 
Metabolism 
AW134794 SLC39A8 solute carrier family-39, member-8 2.7 
AI379894 PPP2CB protein phosphatase-2 (formerly 2A) 2.2 
BC004864 PPP3CC protein phosphatase-3 (formerly 2B; calcineurin A) 2.2 
NM_002779 PSD pleckstrin and Sec7 domain protein 2.2 
NM_006782 ZFPL1 zinc finger protein-like-1 2.2 
U94357 GYG2 glycogenin-2 2.1 
NM_003456 ZNF205 zinc finger protein-205 2.1 
76 
BC005043 MGC31957 hypothetical protein  1.9 
NM_014649 SAFB2 scaffold attachment factor-B2 1.8 
NM_018135 MRPS18A mitochondrial ribosomal protein-S18A 1.7 
NM_007188 ABCB8 ATP-binding cassette, sub-family-B, member-8 1.6 
NM_018411 HR hairless homolog  1.6 
NM_006238 PPARD peroxisome proliferative-activated receptor, delta 1.6 
AA047234 OAZIN ornithine decarboxylase antizyme inhibitor 1.4 
NM_005254 GABPB1 GA binding protein transcription factor  -1.5 
NM_015906 TRIM33 tripartite motif-containing-33 -1.6 
AL525798 FACL3 fatty-acid-Coenzyme A ligase, long-chain-3 -1.7 
NM_004457 FACL3 fatty-acid-Coenzyme A ligase, long-chain-3 -2 
Signal transduction 
D10202 PTAFR platelet-activating factor receptor 2.6 
NM_014716 CENTB1 centaurin, beta-1 2.5 
BC005365 MAP2K7 mitogen-activated protein kinase-7 2.3 
AI860917 PNUTL1 peanut-like 1  2.3 
AI688812 RASGRP2 RAS guanyl releasing protein-2 2.3 
AF028825 DLG4 discs, large homolog-4 2.2 
NM_007327 GRIN1 glutamate receptor, ionotropic,  2.2 
NM_006869 CENTA1 centaurin, alpha-1 2.1 
AJ133822 AGER advanced glycosylation end-product-specific receptor 2 
NM_007369 RE2 G-protein-coupled receptor 2 
AW138374 RHEB Ras homolog enriched in brain-2 2 
X60502 SPN sialophorin  2 
M24900 THRA thyroid hormone receptor, alpha 2 
NM_001397 ECE1 endothelin converting enzyme-1 1.9 
L05666 GRIN1 glutamate receptor, ionotropic 1.8 
AF287892 SIGLEC8 sialic acid binding Ig-like lectin-8 1.8 
NM_014274 TRPV6  transient receptor potential cation channel 1.8 
NM_000479 AMH anti-Mullerian hormone 1.7 
NM_014204 BOK BCL2-related ovarian killer 1.7 
U58856 MRC2 mannose receptor, C-type-2 1.6 
AI991328 CHK choline kinase 1.5 
NM_000908 NPR3 atrionatriuretic peptide receptor-C 1.4 
BG222394 MAPK8IP1 mitogen-activated protein kinase-8 interacting protein-
1 
1.3 
AA460694 KIAA1354 KIAA1354 protein -1.6 
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BG111761 GNG12 G protein, gamma-12 -1.8 
Transport 
U87555 SCN2B sodium channel, voltage-gated, typeII 2.1 
NM_024681 FLJ12242 hypothetical protein  2 
W72053 TGOLN2 trans-golgi network protein-2 -1.6 
AJ131244 SEC24A SEC24 related gene family, member A  -2 
Other 
AK025352 MAST205 serine/threonine protein kinase 2.3 
AI818951 MGC40499 hypothetical protein  2.3 
AK025188 FLJ20699 hypothetical protein  2.2 
AI831055 SFTPC surfactant protein C 2.2 
BC004264 EPHB4 ephrin receptor 2.1 
NM_031304 MGC4293 hypothetical protein  2.1 
D38024 DUX4 double homeobox-4 1.9 
NM_003061 SLIT1 slit homolog-1  1.9 
NM_024821 FLJ22349 hypothetical protein  1.8 
NM_019858 GRCA likely ortholog of mouse gene rich cluster 1.8 
AF023203 NA Homo sapiens homeobox protein  1.8 
NM_030935 THG-1 TSC-22-like 1.8 
NM_025268 MGC4659 hypothetical protein  1.6 
BC000979 DDX49 DEAD (Asp-Glu-Ala-Asp) box polypeptide-49 1.5 
AK021505 NA Homo sapiens cDNA clone  1.5 
NM_018049 GNRPX likely ortholog of mouse guanine nucleotide releasing 
protein 
1.4 
AA018777 NA ESTs 1.2 
AF052151 MTVR1 Mouse Mammary Turmor Virus Receptor homolog-1 -1.3 
AL525412 MYCBP Mycbp-associated protein -1.4 
NM_012311 KIN antigenic determinant of recA protein  -1.5 
NM_018553 HSA277841 ELG protein -1.6 
AA191576 NPM1 nucleophosmin  -1.6 
NM_016628 WAC WW domain-containing adapter with a coiled-coil 
region 
-1.8 
*Fold change is mean  expression for ischemic relative to nonischemic samples.
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 Figure 3.1  Study design to identify and validate a molecular signature that differentiates between ischemic and nonischemic 
cardiomyopathy.  The samples were first divided into a training set of end-stage samples from Johns Hopkins Hospital (JHH) used to 
develop the etiology signature.  It was then validated by determining its sensitivity and specificity in three test sets: end-stage samples 
from the University of Minnesota (UM), post-LVAD samples from both JHH and UM, and endomyocardial biopsy samples from 
newly diagnosed patients at JHH.  Then the end-stage samples were randomly partitioned into training and test sets to identify the 

































































Figure 3.2  Number of genes from the etiology molecular signature that are up- and down-regulated in ischemic cardiomyopathy 
relative to nonischemic cardiomyopathy classified by functional group.  CGM is cell growth/maintenance, CYT is cytoskeleton, DEV 
is development, IMM is immune response, MET is metabolism, OTH is other, SIG is signal transduction, and TRA is transport. 
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Figure 3.3  Hierarchical clustering of genes that comprise the etiology molecular 
signature.  Each row represents a gene and each column represents a sample.  The color 
in each cell reflects the level of expression of the corresponding gene in the 
corresponding sample, relative to its mean level of expression in the entire set of samples.  
Expression levels greater than the mean are shaded in blue, and those below the mean are 
shaded in red.  The samples form two distinct clusters based on etiology.  Arrows denote 
samples that do not appear in their etiology cluster.  ICM denotes end-stage or post-
LVAD ischemic cardiomyopathy and NICM denotes end-stage or post-LVAD 
nonischemic cardiomyopathy. ICMB denotes newly diagnosed ischemic cardiomyopathy 





Figure 3. Independent assessment of gene expression levels by quantitative PCR for select genes in the etiology molecular signature.  
Fold change in expression is in ischemic relative to nonischemic hearts according to qPCR (gray bars) and microarrays (white bars) 
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Lessons learned: gene discovery versus molecular signature analysis 
The pitfalls of gene discovery 
 The two studies contained in this dissertation highlight the complementary yet 
distinct goals and statistical methods involved in gene discovery and molecular signature 
analysis.  Both demonstrate that unique gene expression exists in the two major forms of 
cardiomyopathy.  On one hand, the unique patterns of gene expression can provide 
insight into potential cause-specific therapies for heart failure.   On the other hand, the 
unique patterns of gene expression can function as a diagnostic biomarker.  These two 
analyses are not redundant, since they used different sets of samples, different statistical 
methods, and most importantly, had different purposes.  Given this, it is not surprising 
that only four of the identified genes were shared between the two studies.  However, this 
lack of overlap illustrates a troubling aspect of analyses focused on gene discovery: how 
reliable and biologically valid are the results?  These are the two major pitfalls of gene 
discovery. 
 The problems with reliability are highlighted in Table 2.5.  This table illustrates 
that there is remarkable congruence in the direction and magnitude of differential gene 
expression between published studies of gene discovery in failing and nonfailing hearts.  
However, despite this agreement, these genes represent the minority of genes identified in 
the studies; the majority of differentially expressed genes identified do not overlap, and 
how to resolve this variability between studies is unclear. 
 Analyses of gene discovery also highlight troubling questions regarding 
biological validity.  Two studies attempted to validate the differentially expressed genes 
by confirming not only levels of transcript abundance, but also their corresponding 
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protein products.  However, in both studies, there was little agreement between transcript 
abundance measured on the microarray and the corresponding proteins.53;54  On one hand, 
this lack of agreement is not surprising, since a number of factors affect the measured 
protein abundance, including differences in mRNA localization, processing, stability, 
translation efficiency, as well as posttranslational protein modification and interactions.  
However, while the lack of agreement is not surprising, it is concerning.  Since cellular 
processes are mainly mediated by proteins, mRNA changes unaccompanied by 
corresponding alterations in protein may not be meaningful.  Furthermore, even if protein 
abundance confirms the gene expression levels noted by microarray analysis, a biological 
role for these changes has still not been established. 
 While there is no clear consensus on how to resolve these problems of reliability 
and biological validity in microarray studies focused on gene discovery, one point is 
clear: the role and value of validation differs between gene discovery and molecular 
signature analysis. 
The role of validation 
 Studies of gene discovery have significant merit, in offering valuable hypothesis-
generating insight into possible mechanistic pathways.  Nevertheless, results must be 
interpreted with caution, and confirmation of transcript abundance via a complementary 
method should be only the first step in validating the significance of the differentially 
expressed genes.  The potential novel genetic pathways or targets of cause-specific 
therapies must be further elucidated with studies focused on establishing causality, such 
as in vitro or animal models of deletion or over-expression of the target gene product.   
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 In contrast, microarray analyses focused on molecular signature analyses are less 
vulnerable to problems with reliability and biological validity because their utility is 
confirmed by testing the molecular signature’s predictive accuracy in independent 
samples.  Molecular signature analysis is based upon a pattern of gene expression rather 
than the identity of specific genes.59  The prediction algorithm is able to compare an 
unknown sample and determine how closely it resembles one pattern versus the other; the 
absolute expression of an individual gene carries relatively small weight compared to the 
overall signature.   Thus, validation in molecular signature analysis cannot solely involve 
the confirmation of gene expression levels via a complementary technique.  Nevertheless, 
confirmation of transcript abundance can prove useful to address a different issue:  
whether the molecular signature offers utility independent of the microarray platform 
used to create it.  This is important if disease-specific platforms are developed, as in the 
oncology experience.108;109 
Lessons learned: technical issues in gene expression analysis 
Information management and reproducibility in microarray experiments 
 Given the rapid growth of microarray research and the vast amount of information 
that can be gleaned from a single experiment, there are many challenges in designing 
studies and interpreting the results.  To this end, the Microarray Gene Expression Data 
society (MGED) has developed the Minimum Information About a Microarray 
Experiment (MIAME) standards that are needed to enable the interpretation of the results 
of the experiment unambiguously and potentially to reproduce the experiment.110  
MIAME includes details of the experimental design, sample preparation, hybridization 
procedures, normalization algorithms, and array design.  The ultimate goal is to establish 
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a standard for recording and reporting microarray-based gene expression data, which will 
in turn facilitate the establishment of databases and public repositories and enable the 
development of data analysis tools. 
 Such public repositories exist, including the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO); the European Bioinformatics 
Institute (EMBL-EBI) ArrayExpress repository; and the Center for Information Biology 
Gene Expression (CIBEX) database.  There is also a cardiology-specific repository, the 
Cardiogenomics website (www.cardiogenomics.com), a National Heart Lung and Blood 
Institute-sponsored Program for Genomic Applications.  Many journals currently require 
that submissions comply with the MIAME standard, but not all require that a complete 
data set be submitted to one of three databases prior to manuscripts submission.  
Furthermore, the public repositories do not require that the data be submitted in raw as 
well as normalized fashion, which would be essential for future studies.  Mandatory 
submission of raw microarray data files to public repositories, by promoting collaboration 
among scientists, would be essential for maximizing the utility of microarray research. 
Sample size in microarray experiments 
 Clearly, molecular signature analysis is in its earliest stages in cardiomyopathy, 
and there are many unresolved issues.  For example, there is limited knowledge on the 
sample size required in microarray experiments.  The largest microarray study in 
cardiomyopathy to date has involved 199 samples,54 and in the oncology literature, each 
study has employed fewer than 300 patients.  However, this could be considered a 
strength of these analyses: a succession of smaller studies, performed quickly and with 
the use of improving technology, may surpass larger studies locked into out-of-date 
89 
approaches.63  Furthermore, by randomly partitioning samples as we did in identifying 
and validating a gene expression signature, it is possible to maximize the utility of a 
limited number of samples. 
The source of tissue for analysis 
 To date, microarray analyses in cardiomyopathy have mainly utilized discarded 
myocardial tissue obtained at the time of cardiac transplantation or LVAD placement, 
and there are limitations to this approach.  First, the tissue is obtained from patients late 
in the disease course and thus the conclusions may not be applicable to patients at an 
earlier stage of disease; as we demonstrated, a molecular signature based on etiology in 
end-stage cardiomyopathy is specific to disease stage.75  Second, explanted tissue is 
obtained from different areas of the left ventricle, and there is evidence from microarray 
analysis in mice that regional differences in gene expression exist in the left ventricle.111   
Thus, in the future, microarray analyses in cardiomyopathy will ideally focus on 
endomyocardial biopsy tissue obtained from patients at earlier stages of disease, and we 
have demonstrated that microarray hybridization from endomyocardial biopsies is 
feasible.75 
 Although one commonly invoked limitation of gene expression research in 
cardiovascular disease is the lack of ready access to human heart tissue samples, 
endomyocardial biopsies are frequently  performed to evaluate newly diagnosed 
cardiomyopathy.29;112  Endomyocardial biopsy is a safe and well-tolerated procedure, 
with an overall mortality rate of 0.2%,113 a rate equivalent to that of other routinely 
performed catheterization procedures. 
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 While endomyocardial biopsy could be more widely performed if a valuable 
prognostic or diagnostic test were developed, venipuncture is clearly more accessible.  
Therefore, it is essential to also test the utility of molecular signature analysis in 
peripheral blood leukocyte samples.  In the cancer literature, molecular signatures 
derived from peripheral blood leukocytes offer comparable predictive accuracy to those 
from solid tumor samples in classifying subjects by cancer type and type of therapy.114;115  
This may also be feasible in cardiovascular disease, as peripheral blood molecular 
signatures correlated with biopsy-proven allograft rejection  in cardiac transplant 
recipients116 and cardiac genes in circulating blood are differentially expressed in patients 
with coronary artery disease relative to controls without heart disease.117 
Future perspectives 
Prognosis 
 Knowledge of prognosis is essential for patient education and allocation of 
therapies, especially those that may be costly and invasive.  In the future, it may be 
possible for a patient with a newly diagnosed cardiomyopathy to better understand, 
through an assessment of his or her “prognostic molecular signature,” whether his or her 
ejection fraction and functional status will improve, or whether he or she will go on to 
develop circulatory collapse.  This knowledge may then be used to pursue more 
aggressive management in patients who will do poorly, including earlier evaluation for 
heart transplantation or ventricular assist device placement. 
Individualization of patient management 
 There is also evidence that gene expression may differ based on response to 
therapy in heart failure.  In a study using candidate gene expression analysis, patients 
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with idiopathic dilated cardiomyopathy who improve their ejection fraction in response to 
treatment with beta-blockers had associated changes in the expression of myocardial 
contractility-regulating and hypertrophy-associated genes.118  This lends support to the 
development of molecular signatures that predict which patients will derive benefit from 
heart failure therapies. 
 Another key area where this technology will be helpful is in deciding to pursue 
therapies that may be risky, costly, and invasive, and the implantable cardiac defibrillator 
(ICD) is a prime example.  Although there is clear mortality benefit to ICD implantation 
in all patients with an ejection fraction less than 35%,19 the current consensus is that we 
have not yet identified subsets of high-risk individuals who will benefit most from this 
therapy.119;120  In the future, it may be possible to identify a “sudden cardiac death 
molecular signature,” that identifies cardiomyopathy patients who are at high risk for this 
manner of death. 
 In addition, it would be very useful to predict which patient may have an adverse 
response to therapy.  For example, 3 to 5% of patients receiving anthracycline 
chemotherapy will develop a severe, symptomatic cardiomyopathy, which is usually 
irreversible and may subsequently require cardiac transplantation.121  Although risk 
factors exist, it is currently not possible to predict which patients will sustain serious 
cardiac damage and develop heart failure.  However, if a gene expression profile could 
predict which patients undergoing chemotherapy were at increased risk for anthracycline-
induced cardiomyopathy, chemotherapeutic regimens could be tailored to prevent this 
devastating complication of cancer therapy. 
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 With this evidence of heterogeneity in response to therapy and an association 
between response to therapy and gene expression, we envision developments over the 
next decade in which gene expression-based molecular signatures are used to tailor 
therapies for heart failure patients.  Molecular signatures could also be incorporated into 
clinical trials of new drugs in order to identify those patients who demonstrate the 
greatest benefit or harm from a given therapy.  Using endomyocardial biopsy tissue or 
even peripheral blood leukocytes, it may be possible to identify a patient’s molecular 
signature that will determine their prognosis and response to therapy.  
Conclusions 
 Given the vast array of pharmacologic, device, and surgical therapies for heart 
failure, there are endless examples in which the individualization of management in 
cardiomyopathy patients would be helpful.  With the promise of this technology, it is 
essential understand the opportunities and pitfalls of this burgeoning field, and to design 
future studies to address these important issues. 
 The most powerful and promising application of gene expression profiling with 
microarrays is molecular signature analysis, where a pattern of genes identified by the 
microarray analysis is used as a biomarker to identify or predict a clinically relevant 
parameter.   Molecular signature analysis could augment current clinical and imaging 
modalities used to determine the prognosis and response to therapy of dilated 
cardiomyopathy patients.  There is evidence that this is a feasible strategy in 
cardiomyopathy, with our study identifying and validating a molecular signature that 
differentiates cardiomyopathy patients by etiology. 
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 Although there are unresolved issues in this field, including sample size 
requirements and the source of tissue for analysis, there is still much promise.  The 
ultimate goal of molecular signature analysis will be to contribute towards an 
individualization of the management of heart failure patients, whereby a patient with a 
newly diagnosed cardiomyopathy could, through gene expression analysis, be offered an 
accurate assessment of prognosis, and how individualized medical therapy could affect 
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